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List of Abbreviations 
 
ACT   Actin-like protein  
ADAM33  A disintegrin and metalloproteinase domain-containing protein 33 
ADAMTS12  ADAM metallopeptidase with thrombospondin type 1 motif 12 
ADRB2  2 adrenergic receptor 
Ang1/2  Angiopoietin 1/2 
ANKRD5  Ankyrin repeat domain 5 
BCA   Bicinchoninic acid assay 
BDP   Beclomethasone dipropionate 
BIRC5   Baculoviral IAP repeat containing 5 
BN-BMLA  Bayesian network based Bayesian multilevel analysis of relevance 
CD14   Cluster of differentiation 14 
CHML   Choroideremia-like protein 
CI   Confidence interval 
CNV   Copy number variation 
CO2   Carbon dioxide 
COPD   Chronic obstructive pulmonary disease 
CTLA4  Cytotoxic T lymphocyte associated protein 4 
CYFIP2  Cytoplasmic FMR1 interacting protein 2 
CYSLTR2  Cysteinyl leukotriene receptor 2 
DAG   Directed acyclic graph 
DMEM  Dulbecco’s Modified Eagle Medium 
DMSO  Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
DPP10  Dipeptidyl peptidase 10 
DZ   Dizygotic twins 
ECL   Electrochemiluminescence 
ECM   Extra cellular matrix 
ELISA   Enzyme-linked immunosorbent assay 
eQTL   Expression quantitative trait locus 
EQTN   Equatorin 
ESR1   Estrogen receptor 1 
FAT4   FAT atypical cadherin 4 
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FBS   Foetal bovine serum 
FCERIA  Gene for high affinity IgE receptor I  
FcRII   Low-affinity IgE receptor II 
FDA   Food and Drug Administration 
FDR   False discovery rate 
FENO   Fractional exhaled nitric oxide 
FEV1   Forced expiratory volume in 1 second 
FRMD6  FERM-domain containing 6 
FVC   Forced vital capacity 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
GBD   Global Burden of Disease Study 
GINA   Global Initiative for Asthma Guidelines 
GM-CSF  Granulocyte-macrophage colony-stimulating factor 
GP   General practitioner 
GPR154  G-protein coupled receptor PGR14 
GPRA   G-protein coupled receptor for asthma susceptibility 
GSTP1  Glutathione S-transferase pi 1 
GWAS  Genome-wide association study 
H1   Histamine receptor 1 
H2   Histamine receptor 2 
HDAC   Histone deacetylase 
HLA-DQB1  Human leukocyte antigen DQ  1 
HLA-G  Human leukocyte antigen G 
HRP   Horseradish peroxidase 
HWE   Hardy-Weinberg Equilibrium 
IAP   Inhibitor of apoptosis 
ICS   Inhaled corticosteroid 
IFN   Interferon- 
IFNA   Gene for interferon alpha 
IFNG   Gene for interferon gamma 
Ig   Immunoglobulin 
IL   Interleukin 
IL18R1   Interleukin 18 receptor 1 
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IL7R    Interleukin 7 receptor 
IRAK3   Interleukin 1 receptor associated kinase 3 
ISAAC  International Study of Asthma and Allergies in Childhood 
ITLN1   Intelectin-1 
JAG1   Jagged 1 
JNK   Janus kinase 
KLF15   Kruppel Like Factor 15 
KASP   KBioscience Competitive Allele-Specific PCR 
LABA   Long-acting beta agonist 
LATS1/2  Large tumour suppressor kinase 1/2 
LD   Linkage Equilibrium 
LIFR   Leukaemia inhibitory factor receptor  
LTA   Lymphotoxin  
MAF   Minor Allele Frequency 
MOB1   MOB kinase activator 1 
mRNA  Messenger RNA 
MS4A2  Membrane spanning 4-domains A2 
MST1/2  Mammalian STE20-like protein kinase 1/2 
MZ   Monozygotic twins 
NAT2   N-acetyltransferase 2 
NGS   Next-generation sequencing 
NRP1/2  Neurophilin-1/2 
NSAID  Non-steroid anti-inflammatory drug 
OPN3   Opsin 3 
OR   Odds ratio 
ORMDL3  Orosomucoid-like 3 
OVA   Ovalbumin 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PDZ  Post synaptic density protein, Drosophila disc large tumour 
suppressor, Zonula occludens-1 protein 
PGF   Placental growth factor 
PGF2  Prostaglandin F2 
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PHF11  PHD Finger Protein 11 
PPARGC1B Peroxisome proliferator-activated receptor gamma coactivator 1-
beta 
PTGER4  Prostaglandin E receptor 4 
PVDF   Polyvinylidene fluoride 
Ras   Ras superfamily  
Rho   Rho family of GTPases 
RIPA buffer  Radioimmunoprecipitation assay buffer 
RLT buffer  Guanidine thiocyanate buffer 
RNA   Ribonucleic acid 
ROS   Reactive oxygen species 
rs   SNP reference number 
RT-PCR  Reverse transcriptase PCR 
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TAD   Transcriptional activation domain 
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TB   Transcriptional enhancer factor-binding 
TCR   T cell receptor 
TEAD   TEA domain containing protein 
TEK   Gene for tyrosine-protein kinase receptor 2 
TFF1   Trefoil Factor 1 
Th1   T helper type 1 lymphocyte 
Th2   T helper type 2 lymphocyte 
Tie2   Tyrosine-protein kinase receptor 2 
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UTR   Untranslated region 
VDR   Vitamin D receptor 
VEGF   Vascular endothelial growth factor 
VEGFR  Vascular endothelial growth factor receptor 
WGS   Whole genome sequencing 
YAP1   Yes-associated protein 1 
YM155  Sepantronium Bromide 





1.1. Asthma and Allergy 
1.1.1. General Characteristics 
 
Asthma is a chronic inflammatory respiratory disease influenced by a wide range 
of environmental and genetic factors (Chen, Wong, and Li 2016). It is characterized by 
airflow obstruction due to smooth muscle constrictions and airway inflammation with 
symptoms such as coughing, wheezing, tightness in the chest, bronchoconstriction and 
airway hyperresponsiveness that may remit spontaneously or upon treatment. Further, 
long term inflammation leads to mostly irreversible structural and functional changes in 
the airway smooth muscles called airway remodelling that is characterized by bronchial 
wall thickening and increased vascularity, sub-mucosal gland hyperplasia and 
hypertrophy as well as extracellular matrix (ECM) deposition and angiogenesis (‘New 
NHLBI guidelines for the diagnosis and management of asthma. National Heart, Lung 
and Blood Institute’, 1997) (Figure 1). 
 
Figure 1. Schematic diagram of healthy and asthmatic airways. 
 
Asthma exacerbations may be caused by different environmental triggers. These 
factors, among others, may be grouped into indoor and outdoor stimuli, where indoor 
factors include allergens of dust mites, cockroaches, mice and pets, indoor burning of 
tobacco, wood and biomass, indoor endotoxins or products from Gram-positive bacteria. 
Outdoor factors include viral and microbial pathogens, airborne particles, ozone, diesel 
exhaust particles, pollens, outdoor moulds, tobacco smoke, cold air or humidity. 
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Environmental stimuli also include exercise, occupation or even diet (Ho 2010; Diette et 
al. 2008).  
 
1.1.2. Classification of Asthma and Allergy 
 
Based on which cause initiated asthma or the exacerbation, asthma phenotypes 
can be distinguished. These include allergic-, non-allergic asthma, viral-induced asthma, 
exercise-induced asthma. Within the limits of this thesis, we have included these four 
groups in our analyses and have created subgroups for these asthma phenotypes with the 
help of respiratory specialists (Figure 2). Other asthma types can also be characterized for 
example aspirin-exacerbated respiratory disease that is a combination of asthma, chronic 
rhinosinusitis with nasal polyps and a sensitivity to aspirin or other types of non-steroid 
anti-inflammatory drugs (NSAIDs), pre-asthma wheezing in infants where recurrent 
episodes of the abnormality is likely due to asthma (Martinez et al. 1995), but other 
reasons may exist such as allergies, infection or obstructive sleep apnea. Furthermore, 
there is exacerbation-prone asthma with more frequent visits to the hospital due to 
recurrent asthma attacks, and asthma associated with apparent irreversible airflow 
limitation, where irreversibility may only be defined based on longitudinal studies, a 
progressive development of airway obstruction and treatment irresponsiveness (Pascual 
and Peters 2009), as well as eosinophilic and neutrophilic asthma (Bruijnzeel, Uddin, and 
Koenderman 2015; Patterson, Borish, and Kennedy 2015; Pelaia et al. 2015).  
We have added subgroups to the pre-existing ones included in our analyses, for 
example asthma comorbidities of allergic rhinitis and allergic conjunctivitis, as these are 
the most frequent asthma associated allergic diseases which often occur together (Shaker 
and Salcone 2016; Rosario and Bielory 2011; Lee et al. 2013). Conjunctivitis is an 
inflammatory disease of the eye characterized by flushing, swelling, itching, and watering 
of the eyes whereas rhinitis is an inflammation of the nasal mucosal surface indicated by 
sneezing, a runny and/or stuffy nose, and post-nasal dripping. In different studies, 
between 50-65% of patients with rhinitis also had conjunctivitis, but conjunctivitis could 
also exist without rhinitis (Rosario and Bielory 2011). Our subgroups also include clinical 
parameters of asthma such as total IgE level and absolute eosinophil concentrations, 
which have been found to correlate with asthma severity. In children, the most frequent 






Figure 2. Subgroups of asthma phenotypes included in our analyses. Asthma 
phenotypes may overlap. 
 
1.1.3. Diagnostic Criteria 
 
It is well-known that asthma is not a single disease but rather a series of 
overlapping individual diseases or phenotypes, each defined by its unique interaction 
between genetic and environmental factors (Lötvall et al. 2011; Borish and Culp 
2008). Moreover, non-asthmatic disease symptoms may also overlap with asthma. 
Diagnosis of the disorder may therefore be difficult, but crucial in terms of the therapy 
applied, morbidity and mortality. There are guidelines, such as The Global Strategy for 
Asthma Management and Prevention 2015 report update or the National Institutes of 
Health Guidelines for the Diagnosis and Management of Asthma Expert Panel Report-3, 
for an easier diagnosis (Global Initiative for Asthma; National Asthma Education and 
Prevention Program 2007). The detailed history of symptoms and a physical exam aids 
diagnosis of asthma subtypes. Measurements of forced expiratory volume in 1s (FEV1) 
and forced vital capacity (FVC) and especially their ratio, FEV1/FVC are good indicators 
of airflow obstruction. Specialists also examine diffusing capacity or lung volumes and 
may apply Broncho provocation (Global Initiative for Asthma; National Asthma 

















It is important to understand the pathophysiology of asthma which has still not 
been fully elucidated. The description of the course of the disease goes beyond the scope 
of this paper, therefore, here I only summarize the main aspects of asthma pathogenesis. 
Asthma is a chronic inflammatory disorder, where many cells and elements of the 
immune response play a role in its pathogenesis. Once the body encounters an allergen, 
virus or a noxious agent the immune system will be activated and in genetically 
susceptible individuals will over-react. In allergic asthma, dendritic cells, that are antigen-
presenting cells, encounter the allergen and migrate to lymph nodes to present the peptide 
to naïve T lymphocytes that will be activated to mature into T helper 2 (Th2) cells with 
the aid of other regulatory cells (Kuipers and Lambrecht 2004). T lymphocyte 
subpopulations among others, include Th1 and Th2 cells with distinctive cytokine profiles 
that include interleukin-12 (IL-12), interferon- (IFN) and IL-4, -5, -9 and -13, 
respectively. There are several factors that determine the Th1/Th2 balance. According to 
the ‘hygiene hypothesis’ the Th1/Th2 balance may be skewed towards the cytokine 
profile of Th2 cells in newborns. This imbalance is usually lifted by infections, the 
presence of older siblings, rural environment or daycare attendance at an early age, that 
all entail a Th1 response. On the other hand, urban environment, the use of antibiotics or 
sensitization to diverse allergens do not involve Th1 cytokines, hence the early imbalance 
remains making the individual more susceptible to allergies, asthma or other chronic 
inflammatory diseases (Sears et al. 2003; Horwood, Fergusson, and Shannon 1985; Gern, 
Lemanske, and Busse 1999; Gern and Busse 2002; Eder, Ege, and von Mutius 2006). 
The release of Th2 cytokines activates a cascade of events that lead to airway 
inflammation and in the long run, airway remodelling. IL-4 aids the differentiation of Th2 
cells and along with IL-13 they play a role in the formation of IgE immunoglobulins 
through the induction of class-switching of B-lymphocytes, hence IgE receptors will be 
produced once they have become plasma cells. IgE receptors are important actors in 
hypersensitivity type I and diseases such as allergic asthma, atopic diseases or allergic 
conjunctivitis. IL-5 and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
help the maturation of eosinophil granulocytes in the bone marrow and after infiltration 
to the inflamed airways their prolonged survival, respectively. Furthermore, tumour 
necrosis factor- (TNF-) further enhances the inflammatory processes in the lungs 
(Chung and Barnes 1999).  
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Beside eosinophil infiltration, other immune cells, such as neutrophils, 
macrophages or mast cells also transmigrate into the airways. Eosinophils have increased 
numbers in asthmatic airways. By releasing pro-inflammatory mediators and cytokines, 
they contribute to the inflammatory response. It has been shown that higher numbers of 
eosinophils correlate with asthma severity. Mast cells play a critical role in the 
pathogenesis of allergic diseases, as having many IgE receptors on their surface allows 
these immunoglobulins to be physically cross-linked by allergens, hence degranulation 
of the mast cells begin, which then empty bronchoconstrictors, such as histamine, 
leukotrienes or prostaglandins into the surrounding tissues (Boyce 2003; Robinson 2004). 
Histamine mediates oedema and mucus secretion as well via its histamine receptors 1 
(H1) and 2 (H2), respectively (White 1990). Leukotrienes not only influence airway 
smooth muscle, but also recruit neutrophils (Gelfand and Dakhama 2006). Among several 
types of prostaglandins, PGF2 causes direct constriction of airway smooth muscles. It 
has been shown that upon PGF2 treatment asthmatics had an 8000-fold increase in 
sensitivity to it compared to healthy subjects (Mathé et al. 1973). It has been suggested 
that airway hyperresponsiveness also has a relation to the increased numbers of mast cells 
found in the airway smooth muscle. Further, mast cells not only release cytokines upon 
allergen contact, but in exercise-induced asthma they may also be activated by osmotic 
changes (Brightling et al. 2002). Macrophages may be activated by IgE receptors as well, 
releasing more inflammatory mediators and other cytokines enhancing the inflammatory 
response (Peters-Golden 2004). The role of neutrophils remains unclear in the 
pathogenesis of allergic diseases, but elevated numbers have been found in the airways 
of more severe asthmatics (Fahy et al. 1995; Wenzel 2006; Wenzel et al. 1997).  
Epithelial cells of the airway also play a role in asthma. These cells lining the 
airways have a barrier function and they also maintain tissue homeostasis (Moheimani et 
al. 2016). By releasing more pro-inflammatory mediators during the inflammatory 
processes in asthma, epithelial cells may also suffer injury. Repair mechanisms in 
asthmatic patients are impaired, further worsening the controlled state of asthma. 
Oxidative stress also has an effect on the bronchial epithelium in asthma. 
Oxidative stress is the imbalance between the production of increased oxidative sources 
and the impaired mechanisms of detoxifying the reactive intermediates and repairing the 
caused damage (Holguin 2013). Reactive oxygen species (ROS) are produced either upon 
environmental exposure to air pollution of gases and particulate matter or the local 
inflammation will secondarily induce the production of ROS (Bowler 2004; Ghio, 
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Carraway, and Madden 2012). Oxidative stress is associated with inflammatory cell 
activation and hence the production of pro-inflammatory mediators (Paredi, Kharitonov, 
and Barnes 2002; Wood, Gibson, and Garg 2003). The increased amount of ROS results 
in oxidative lipid peroxidation and DNA damage, further aggravating inflammation and 




To date there is no cure for asthma. It is a very complex disease with many factors, 
pathways, mechanisms that play a role in the pathophysiology of asthma. Which 
medication an asthmatic individual will take depends on age, what triggered their asthma, 
symptoms and whether the drug is effective. It is important for patients to have controlled 
asthma regardless of the severity of their disease. There are several types of long-term 
and short-term asthmatic medications. Long-term medications help to maintain a 
controlled asthmatic state on an everyday basis so that the incidence of an asthma attack 
is lower, while short-term drugs are a quick relief in case of such an attack.  
The most essential drug among long-term medications is inhaled corticosteroids 
(ICS), which are anti-inflammatory medicines (e.g. Budesonide (Pulmicort), Fluticasone 
(Flovent)). ICSs reduce airway inflammation by down-regulating pro-inflammatory 
proteins (Adcock, Ito, and Barnes 2004; De Bosscher, Vanden Berghe, and Haegeman 
2003), reversing components of airway remodelling, such as increased vascularity of the 
bronchial wall (Chanez et al. 2004), suppressing the production of chemotactic mediators 
and adhesion molecules that attract immune cells to the site of inflammation (eosinophils, 
dendritic cells, mast cells, lymphocytes) and also by inhibiting their survival (Schwiebert, 
Stellato, and Schleimer 1996). ICSs are better than orally taken corticosteroids, because 
they locally treat inflammation, rather than causing side-effects. Leukotriene modifiers 
are also effective oral anti-inflammatory drugs (e.g. Zafirlukast (Accolate), Montelukast 
(Singulair)), but in some cases, may cause side-effects of depression, aggression or 
agitation. Long-acting beta agonists (LABAs) (e.g. Salmeterol (Serevent), Formoterol 
(Foradil)) are inhaled drugs taken with ICSs enhancing their effects by suppressing 
inflammatory genes (Korn et al. 1998) and increasing the localization of glucocorticoid 
receptors in the nucleus for a better uptake of the medication (Eickelberg et al. 1999). On 
the other hand, taken alone, LABAs may increase the risk of severe asthma attacks. 
Theophylline, also a bronchodilator and anti-inflammatory drug is used in low doses next 
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to ICSs. Theophylline increases the activity of histone deacetylase (HDAC), which in 
turn reduces the number of eosinophils. Because ICSs activate HDAC through a different 
mechanism, it has been suggested that the low dose of theophylline enhances the anti-
inflammatory effect of ICSs both in asthma and chronic obstructive pulmonary disease 
(COPD) (Cosio et al. 2004; Hossny et al. 2016). 
Short-term asthma medications include short-acting beta agonists (SABAs) which 
offer ease of symptoms within minutes once inhaled through a nebulizer directly to the 
airways (e.g. Metaproterenol, Levalbuterol (Xopenex)). Orally or intravenously taken 
corticosteroids upon an asthma attack are also very effective in treating episodes of 
asthma attacks. In such case, the most used corticosteroids are prednisone, prednisolone 
or methylprednisolone, which should not be taken for long periods of time as may cause 
side-effects of weakness, weight gain, mood or behaviour changes, etc. 
There are of course many approaches to target different factors in asthma that lead 
to a decrease in the inflammation in the airways. For instance, omalizumab is a humanized 
antibody (IgG1k) against IgE antibodies, one of the key players in asthma pathogenesis. 
It has been approved in the 2000s in the United States by the Food and Drug 
Administration (FDA), as well as in the European Union to treat patients 12 years-of-age 
or older (Allergic Asthma and CIU Treatment | XOLAIR® (Omalizumab)). It is used in 
cases of corticosteroid resistance, but due to its higher price and only a few long-term 
trial studies, it is not yet frequently used nor it is administered for longer time-periods 
(Chang et al. 2007; Humbert et al. 2014; Normansell et al. 2014; Schulman 2001). 
Furthermore, several drugs have been developed to target cytokines IL-5, IL-4 or IL-13 
with antibody therapy. All of these medications are only effective in eosinophilic asthma 
phenotypes, but unfortunately minute non-eosinophilic asthma biomarkers are available 
to use in the search for potent therapies (Guilleminault et al. 2017). 
 
1.2. Epidemiology of Asthma 
 
 It is well known that there is an increasing number of persons with asthma and/or 
allergies. The higher numbers of patients burden the countries both financially and 
socially. Many factors must be included in order to gain a complete knowledge of the 
burden of the disease. These include the number of adult and child patients in a country, 
the number of hospital visits, the cost of their treatment, morbidity (e.g. number of days 
missed from school or place of work/year) or mortality.  
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According to the Global Asthma Report 2014 that is based on the Global Burden 
of Disease Study (GBD) between 2008 and 2010 it has been estimated that around 334 
million people suffer from asthma world-wide. Furthermore, there was an increase in the 
number of asthmatics according to the 2011 report based on 2000-2002 population data, 
where 235 million people had asthma globally (The Global Asthma Report 2014). This 
increase may perhaps be due to better and more precise diagnosis of asthma phenotypes 
(Carr and Bleecker 2016). Moreover, it is estimated that due to incomplete data, these 
numbers may be higher. The International Study of Asthma and Allergies in Childhood 
(ISAAC) estimated that around 14% of all the children in the world have asthma each 
year (Lai et al. 2009). The GBD study found that asthma is the fourteenth in number of 
years lost to asthma-associated morbidity and mortality world-wide (Walter et al. 2015). 
 In the USA in 2013 it was predicted that 16.5 million adults (8.3% of population) 
and 6.1 million children (7% of population) have asthma. The disease is more prevalent 
in women compared to men, also more common in children, than in adults, furthermore, 
it is more frequent in boys compared to girls. Asthma was the leading cause of 
absenteeism in children, where 50% of children missed school for at least 1 day every 
year, in 2013 this meant 13.8 million missed school days. Asthma morbidity is similar in 
adults, as 14 million days of work is missed each year. Although in 2014 3651 people 
died from asthma in the USA, death rates have decreased by 26% since 1999 
(https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf, 
https://www.cdc.gov/asthma/most_recent_data.htm).  
The cost of asthma in the USA is $56 billion/year, which means a $3259 per 
person. The yearly cost of the disease in Europe is €19.3 billion 
(https://www.cdc.gov/asthma/impacts_nation/), whereas in Asia-Pacific the cost varies 
between $184 and $1189 per person (www.globalasthmareport.org/burden/burden.php). 
 The Bulletin of the Hungarian Korányi Pulmonology Institute summarized the 
epidemiology of several pulmonology related diseases including asthma. According to 
the study, in which information of registered asthma patients were collected from all 
Hungarian dispensaries, in 2013, 282 754 people were affected by asthma, which means 
a 2.8% prevalence in Hungary (Csoma et al. 2016). The yearly increase in number of 




Figure 3. Diagram showing morbidity rates of asthma patients collected from all 
Hungarian dispensaries. (Csoma et al. 2016) 
 
1.3. Genetic Background 
1.3.1. Genetic Methods and Results in the Research of Asthma and Allergy 
 
 Asthma is a multifactorial disorder, considering that apart from several small 
effect genes and variations that may also be inherited in an additive fashion, 
environmental factors also play a key role in the development of such diseases. With the 
rapid advances in genetics and genetic technologies, the amount of research of complex 
disorders have become substantial, however, our understanding of the mechanisms of 
their inheritance is very limited. 
 The heritability of asthma is estimated by the comparisons of correlations and 
concordance rates of monozygotic (MZ) and dizygotic (DZ) twins. According to twin 
studies, 36-77% of asthma is heritable (Duffy et al. 1990; Harris et al. 1997; Koppelman, 
Los, and Postma 1999; Nieminen, Kaprio, and Koskenvuo 1991), where the concordance 
of MZ twins is 0.74 and 0.35 of DZ twins, presenting a significant difference (Liu, Spahn, 
and Leung 2011). Furthermore, when neither of the parents have asthma, the likelihood 
of the children having the disease is 11-13%, but when both parents have asthma, this rate 
is 50-70% (Barnes and Marsh 1998), also showing the importance of the genetic 























Morbidity in registered patients of Hungarian dispensaries 
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 Essentially, there are three different types of genetic studies to elucidate the 
genetic background of complex diseases. These include candidate gene association 
studies, genome-wide association studies (GWASs) and whole genome sequencing 
(WGS). 
 Candidate gene association studies analyse the relationship of a prespecified gene 
or genetic region and a given disease or phenotype by comparing variation frequencies 
between cases and controls. The previously determined genes are chosen based on the 
protein’s function or role in the disease. There are more than 1000 candidate gene 
association studies of asthma, from which 120 genes have been identified to have a 
relationship with the disorder (March, Sleiman, and Hakonarson 2011). There are 54 
genes found to be associated with asthma that were reproduced in 2-5 independent 
studies. Fifteen genes were found to be associated with the disease in 6-10 independent 
studies, whereas only 10 were found in more than 10 independent investigations. These 
ten, most likely to indeed have a functional role in asthma, include IL-4, IL-13, 2 
adrenergic receptor (ADRB2), major histocompatibility complex, class II, DQ  1 (HLA-
DQB1), TNF, lymphotoxin  (LTA), high affinity IgE receptor (FCERIA), IL-4 receptor 
(IL4R), CD14, and a disintegrin and metalloproteinase domain-containing protein 33 
(ADAM33) (Basehore et al. 2004; Haller et al. 2009; Howard et al. 2002; Kabesch et al. 
2006; Liggett 1995; Munthe-Kaas et al. 2008; Potaczek, Okumura, and Nishiyama 2009; 
Potter et al. 1993; Pykäläinen et al. 2005; Randolph et al. 2004; Suttner et al. 2009; Van 
Eerdewegh et al. 2002; Vladich et al. 2005; Wu et al. 2010; Zhou et al. 2009). 
 Unfortunately, candidate gene association studies cannot give a full picture of the 
complex genetic background of diseases such as asthma, because multifactorial diseases 
develop through many inherited genetic variations that also influence each other, while 
environmental factors also contribute to the formation of the disorder. This problem was 
partially solved by WGS, which is a hypothesis-free research tool examining hundreds of 
microsatellite markers in affected siblings. Thus, many 10-20 million base pair regions  
have been identified to contain candidate genes for asthma and atopy. These regions need 
to be restricted to find the disease susceptibility genes or variations, which is done by 
positional cloning. This technique begins with taking a linked marker in a region and 
depicting the area in its proximity by several levels of recombination. This task was 
daunting until the results of the Human Genome Project were available to search on a 
computer, for a much easier identification of variations in a given region on the DNA 
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(Jorde, Carey, and Bamshad 2010). WGS and positional cloning have identified the 
following among others. ADAM33, dipeptidyl peptidase 10 (DPP10), G-protein coupled 
receptor for asthma susceptibility (GPRA), human leukocyte antigen G (HLA-G), 
cytoplasmic FMR1 interacting protein 2 (CYFIP2) or orosomucoid-like 3 (ORMDL3) 
(Allen et al. 2003; Laitinen et al. 2004; Moffatt et al. 2007; Nicolae et al. 2005; Noguchi 
et al. 2005; Van Eerdewegh et al. 2002). 
 Technical advances in genetics, such as microarrays or next-generation 
sequencing (NGS) have led to the evolution of GWASs. These case-control studies allow 
millions of markers (single nucleotide polymorphisms (SNPs), or copy number 
variations, (CNVs)) to be investigated in large populations with a given phenotype (Jorde, 
Carey, and Bamshad 2010). Many genes and regions have been identified with high-
throughput GWASs (Table 1). On the other hand, GWASs also faced a problem of 
’missing heritability’. Researchers expected previously identified susceptibility genes 
with a strong cumulative effect to be replicated during the association study, however the 
results could not be reproduced. In this regard, the analysis of GWAS results is essential, 
as well as the development of new techniques for the identification of genetics regions, 





Table 1. Asthma or asthma-associated phenotype susceptibility genes and regions. 
Adapted from Gu and Zhao, 2011 (Gu and Zhao. 2011). 
Chromo-
some 
Locus Candidate genes 
1 1p36,1qter,1q23 FCER1A, OPN3, CHML, IL10 
2 2q14,2q32,2q33,2p DPP10, IL18R1, CTLA4, CD28 
3 3q21-q22,3q21.3,3p TLR9 
5 5q31-q33,5q31,5p13,5p15,5q23.3 IL4, IL9, ZFR3, LIFR, PTGER4, 
ADAMTS12, IL7R 
6 6p21,6q24-q25,6q25.3 HLAG, ESR1, TNF 
7 7p14-p15,7q GPR154 
8 8p23.3-23.2 NAT2 
9 9p1,9p21,9p22 TLE4, IFNA 
11 11q13,11q21,11q,11p14 MS4A2, GSTP1 
12 12q13.12-q23.3,12q13-
12q24,12q21,12q24.31,12q24.33 
SFRS8, CD45, IFNG, IRAK3, 
VDR 
13 13q14,13q PHF11, CYSLTR2 
14 14q11.2,14q13-q23,14q24,14q23 TCR, ACT 
17 17q21 ORMDL3 
19 19q13,19q13.3 FCER2 
20 20q13,20p12 ADAM33, JAG1, ANKRD5 
21 21p21 - 
x Xp, Xq - 
 
 
1.3.2. Apoptosis in Asthma 
 
It is well-known, that apoptosis is a key feature in the pathomechanism of asthma 
(Vignola et al. 1999). The most reviewed process is eosinophil-clearance, which is 
impaired in asthmatic patients, hence the high numbers of eosinophils accumulated in the 
bronchial tissues will neither go through apoptosis, nor be cleared by phagocytosis of 
macrophages (Kankaanranta et al. 2000; Walsh 2000; Woolley et al. 1996). Additionally, 
it has been shown that the lack of eosinophil apoptosis in asthmatics correlates with 
disease severity (Duncan et al. 2003). 
The balance between cell apoptosis and survival depends on the control and 
maintenance of different regulatory elements and pathways. For instance, the members 
of the inhibitor of apoptosis protein (IAP) family not only inhibit apoptotic pathways in 
a caspase-dependent manner, they also play a role in the regulation of cell cycle and cell 
division, proving that such regulatory elements have a much more complex function than 
DOI:10.14753/SE.2020.2225
 20 
initially thought. Furthermore, the aberrant expression of the members of this protein 
family results in pathologic cell functioning and uncontrolled cell division (Altieri 2010).  
Baculoviral IAP repeat containing 5 (BIRC5), also called survivin is an important 
anti-apoptotic member of the IAP family. BIRC5 has been previously thought to be only 
expressed in foetal tissues during growth. Moreover, it is abnormally expressed in 
cancerous tissues, hence being a featured target of therapeutic research (Altieri 2010). 
Recently, it has been shown that BIRC5 has additional roles in inflammatory mechanisms 
and disorders, such as asthma (Altznauer et al. 2004; Valentin et al. 2009; Vassina et al. 
2006). Furthermore, our research group has found several important aspects of BIRC5 in 
asthma. Namely, that the mRNA level of Birc5 in ovalbumin (OVA) induced asthmatic 
mouse model was significantly increased compared to normal mice (fold-change of 5.94, 
p=0.001) (Tölgyesi et al. 2009). This result was replicated by Tumes et al, who also found 
that in mice, the mRNA and protein expression of Birc5 found in the bronchoalveolar 
fluid correlated with the number of eosinophils (Tumes, Connolly, and Dent 2009). Our 
research group has further shown, that the gene expression level of BIRC5 was 
significantly higher in asthmatic patients compared to healthy controls, and both the gene 
expression level and one of the studied variations, rs9904341, were significantly 
correlated with the eosinophil ratio found in the induced sputum of asthmatics (Ungvári 
et al. 2012a). 
Furthermore, our group’s previous results have shown that the gene expression of 
FERM-domain containing 6 (FRMD6) is significantly decreased in both the OVA-
induced mouse model, as well as asthmatic patients compared to controls. Additionally, 
a gene polymorphism has been shown to be associated with asthma verified by both 
frequentist and Bayesian statistical approaches (Ungvári et al. 2012b). FRMD6 is the 
upstream activator of the Hippo signalling pathway, which also regulates the expression 
of several proteins, such as BIRC5 (Ungvári et al. 2012a; Ungvári et al. 2012b).  
The Hippo pathway is highly conserved from Drosophila melanogaster to 
mammals and regulates organ size via promoting apoptosis and inhibiting cell 
proliferation in the embryonic stages of development (Huang et al. 2016; Yu, Zhao, and 
Guan 2015). Its name originates from the Drosophila Hippo protein kinase (Hpo), which 
produces tissue overgrowth or „hippopotamus-like” phenotype upon mutations in its 
coding gene. It is still not exactly known whether the pathway is regulated by 
determinants of cell polarity and cell-cell junctions, mechanical cues of the cell, soluble 
factors regulating Hippo members or metabolic status, like cellular energy and oxygen 
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stress (Yu, Zhao, and Guan 2015) (Figure 4). However, it has been proposed that FRMD6 
(also known as Willin) influences the activity of the Hippo pathway by turning on its 
central kinase cascade (Angus et al. 2012). The members of this signalling cascade, 
mammalian STE20-like protein kinase 1 and 2 (MST1/2) and large tumour suppressor 
kinase 1 and 2 (LATS1/2) with scaffold proteins salvador family WW domain containing 
protein 1 (SAV1) and MOB kinase activator 1 (MOB1), respectively, phosphorylate one 
another to inhibit yes-associated protein 1 and tafazzin (YAP1/TAZ), the main effectors 
of the pathway (Harvey and Tapon 2007; Harvey, Pfleger, and Hariharan 2003; Huang et 
al. 2005; Jia et al. 2003; Justice et al. 1995; Lai et al. 2005; Lange et al. 2015; Pan 2007; 
Wu et al. 2003; Xu et al. 1995). YAP1/TAZ, upon phosphorylation on several serine sites 
by its upstream regulators, are sequestered in the cytoplasm by 14-3-3 proteins, unable to 
enter the nucleus, then, they may also be degraded by proteasomes (Piccolo, Dupont, and 
Cordenonsi 2014). YAP1 and TAZ are transcriptional coactivators that bind to 
transcription factors when active, such as TEA domain containing proteins (TEAD), 
SMAD family members (SMAD) or tumour protein P73 (TP73), to regulate the 
expression of anti-apoptotic, (e.g. BIRC5) or apoptotic genes that play a role in cell 
differentiation, survival and migration (Alarcón et al. 2009; Strano et al. 2001; Vassilev 
et al. 2001).  
Figure 4. Examples of signals and pathways regulating YAP1 activity, including the 




The gene, YAP1, that codes for the main effector of the Hippo pathway, is located 
on the long arm of chromosome 11. It is a 123 kb gene comprising 10 exons and 9 introns 
that will be a 54 kDa protein after translation. YAP1 contains a transcriptional enhancer 
factor-binding domain (TB), a 14-3-3 binding site, two WW domains that aid the binding 
and interaction with LATS kinases, as well as playing a role in the regulation of 
transcription, cell transformation and tissue growth (Sudol and Harvey 2010; Zhang et al. 
2010). Furthermore, YAP1 has an SRC homology 3 domain (SH3) binding motif, a 
transcriptional activation domain (TAD), a PDZ binding domain and several serine 
phosphorylation sites throughout its sequence (Iglesias-Bexiga et al. 2015) (Figure 5).  
 
Figure 5. Simplified schematic diagram of YAP1 protein structure. N: N-terminus, C: C 
terminus 
 
YAP1 behaves as an oncogene, that has been investigated and applied as a therapeutic 
target in different types of cancers, such as liver, prostate, thyroid, gastric, or lung cancer. 
Besides embryonic tissues, where YAP1 plays an important role in, for example, lung 
maturation and postnatal airway homeostasis, it is widely expressed in respiratory 
epithelial cells of the embryonic and mature lung, where the Hippo/YAP1 signalling 
regulates epithelial cell proliferation and differentiation (Mahoney et al. 2014). 
Furthermore, in mice it has been demonstrated that YAP is dynamically regulated during 
regeneration of the airway epithelium following lung injury suggesting a possible role of 
Hippo/YAP1 signalling in the pathogenesis of acute and chronic lung diseases (Lange et 
al. 2015). 
  
1.3.3. Angiogenesis in Asthma 
 
Processes such as cytokine production, inflammatory cell infiltration to the lungs, 
injury to epithelial cells or apoptosis all play an important role in the development and 





















and angiogenesis are also key aspects of asthma (Bischof et al. 2009). Increased 
vascularity and angiogenesis in asthmatic patients may cause an increase in airway wall 
thickness, and hence, airway occlusion (Makinde and Agrawal 2011). Moreover, Salvato 
has found that the number of vessels as well as vascularity have a positive correlation 
with asthma severity (Salvato 2001). 
Angiogenesis is the process where new blood vessels form from pre-existing ones 
(Madeddu 2005). It takes place in embryonic development, as well as adults, where 
angiogenesis is an important feature of both many physiological and pathological 
processes. Physiological processes include hair growth, the female reproductive cycle, 
wound healing, or bone repair (Carmeliet 2005). On the other hand, uncontrolled 
angiogenesis is present in cancer, rheumatoid arthritis, diabetes or psoriasis, but poor 
angiogenesis results in myocardial or brain ischemia or non-healing ulcers (Bellou et al. 
2013; Costa and Soares 2013; Zachary and Morgan 2011). Angiogenesis is regulated by 
several molecules, such as vascular endothelial growth factor (VEGF), which is the most 
distinct growth factor for the vascular endothelium (Breier et al. 1992; Ferrara 2002; 
Shweiki et al. 1993). There are several growth factors in this family that either primarily 
regulate the growth of blood vessels or lymphangiogenesis, furthermore, placental growth 
factor (PGF) is expressed in the placenta or certain types of tumours (De Falco, Gigante, 
and Persico 2002; Ferrara 2002; Maglione et al. 1991). The VEFG family function 
through VEGF receptors (VEGFR), VEGFR-1, -2 and -3 (Ferrara 2002), that also have 
coreceptors, Neurophilin-1 and -2 (NRP1 and -2) that increase VEGF affinity for VEGFR 
(Becker et al. 2005; Gluzman-Poltorak et al. 2000; Soker et al. 1998) (Figure 6). Other 
regulators of angiogenesis are angiopoietins, like Ang1 and Ang2 in humans. These are 
glycoproteins that have both been characterized by acting as ligands for tyrosine-protein 
kinase receptor, Tie2 (Saharinen et al. 2008; Yuan et al. 2009). Ang1 and Ang2 have a 
similar affinity for binding to Tie2. Ang1 stimulates kinase activity by binding to Tie2; 
on the other hand, Ang2 may act as an agonist or an antagonist for Tie2 in a tissue- and 
cell-dependent manner (Augustin et al. 2009). Ang1 provides an anti-inflammatory effect 
on blood vessels during angiogenesis, whereas Ang2 and vascular endothelial growth 







Figure 6. Schematic diagram of VEGFs, VEGF receptors and their primary functions. 
Adapted from Detoraki et al, 2010. (Detoraki et al. 2010) 
 
 Tie2 is encoded by the TEK gene in humans and is found on the short arm of 
chromosome 9. It plays a role in angiogenesis, endothelial cell survival, proliferation, 
migration, adhesion and cell spreading, as well as the reorganization of the actin 
cytoskeleton or the maintenance of vascular quiescence (Audero et al. 2004; Cascone et 
al. 2003; Fukuhara et al. 2008; Martin et al. 2008; Saharinen et al. 2008; Yuan et al. 2009; 
Lee et al. 2004). Tie2 also has an anti-inflammatory effect by averting the leakage of pro-
inflammatory elements from the blood vessels into the surrounding tissues. It has been 
found that Tie2 receptor mRNA and protein are abundantly expressed in the lungs 
(Kanazawa 2007). In a recent genome wide association study in European American 
populations the strongest signals were identified at the 9p21.2 locus consisting of four 
SNPs in weak LD with each other and spanning three genes (EQTN (Equatorin), MOB3B 
(MOB kinase activator 3B), TEK) (Almoguera et al. 2016). It was hypothesized that, 
based on its function, variations in the TEK gene were responsible for the association. In 
another study, three non-linked expression quantitative trait locus (eQTL) SNPs were 
identified in the introns of the TEK gene, which all associated with lower TEK gene 
expression in a HapMap3 cohort and increased risk for developing acute respiratory 
distress syndrome (Ghosh et al. 2016).  
The Tie2 pathway also has an important role in the development and function of 
the eye and the TEK gene is highly expressed in the Schlemm’s canal endothelium in the 
eye (Souma et al. 2016). Mutation in the TEK gene is associated with primary congenital 
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glaucoma and Tie2 is a highly-investigated target in different eye diseases like subretinal 
and choroidal neovascularization, macular oedema or diabetic retinopathy (Campochiaro 
and Peters 2016; Campochiaro 2015; Tan et al. 2016).  
 
1.4. Previous Results of Ovalbumin-Induced Mouse Model of Asthma 
 
 Our research group has previously developed an ovalbumin-induced mouse model 
of asthma and have carried out a whole genome gene expression microarray analysis on 
different healthy and asthmatic mouse groups. Using a high-throughput microarray 
technology may lead to greater insights into new genes and pathways regulating the 
development of asthma. This study has been carried out by Tölgyesi et al and the details 
can be found in the GEO database with the record number GSE11911. Therefore, here, I 
only summarize the experimental setup and findings that are relevant for our following 
analyses.  
 Six- to eight-week-old, female, pathogen-free BALB/c mice were used in the 
experiment that were kept on an OVA-free diet in order to senzitize them to the 
compound. All together, 4 groups of mice have been created, where one of them received 
placebo (PBS) during the allergen challenge which comprised the control group. The 
other asthmatic groups received OVA during the allergen challenge, where groups 1 and 
2 comprised the mice from which BALF and lung tissue was collected 4 hours after the 
first and third allergen challenge on days 28 and 30, respectively. From group 3 mice, we 
have collected BALF and lung tissue 24 hours after the third allergen challenge on day 
31. From lung tissues, RNA was isolated for the whole genome gene expression analysis 
and mRNA levels have been compared between control and asthmatic mice. As a result, 
533, 1554 and 1134 genes showed a larger than 2-fold expression change that were 
statistically significant in groups 1, 2 and 3 compared to the control group, respectively. 
Furthermore, 861 transcripts showed a statistically significant, larger than 2-fold 
difference in gene expression between the asthmatic groups (Tölgyesi et al. 2009). These 
data have been used for further analysis in order to find orthologous genes in humans that 
may influence the development of asthma by being differentially regulated on an mRNA 
or DNA level. 
 We have chosen 60 genes based on the results of this study. Our main reasons 
for considering a gene cover several aspects. Firstly, a gene having a larger than 2-fold 
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expression change between asthmatic and control groups. Secondly, a gene (protein) 
having a potential role in the pathogenesis of asthma. Thirdly, finding previous 
scientific results for a given gene. And last, having scientific novelty (Temesi et al. 
2014). These criteria led to the selection of a variety of genes that may be found in 
Table S2. 
 
1.5. Current Shortcomings in the Research of Asthma and Allergy 
 
 Based on the above, it is clear that asthma is a prevalent, often severe, complex 
disorder that is yet impossible to cure. Understanding the mechanisms and pathways of 
the disease, its pathogenesis, its genetic background will bring solutions to asthma one 
step closer. 
 Our research is the very first to identify and hypothesize the Hippo pathway to 
play a role in a phenotype of asthma, as well as a variation of the TEK gene to act in 
allergic conjunctivitis. Although research of apoptosis and angiogenesis in asthma is a 
small piece in a bigger picture, nonetheless, such scientific contributions may advance 






 Our goal was to study the genetic and genomic background and the pathogenesis 
of childhood asthma and its associated phenotypes. The main objectives can be 
summarised as follows. 
 
1. Investigation of the role of the Hippo signalling pathway in asthma 
• Evaluating the differences in gene expressions of seven Hippo 
pathway genes between asthmatics and healthy subjects based on 
previous results of Ungvári et al. (Ungvári et al. 2012a; Ungvári et al. 
2012b) 
• Assess relationship of polymorphisms (tagSNPs) spanning the whole 
of YAP1 gene (based on above results) and asthma and its phenotypes 
by estimation of allele frequencies between asthma patients and 
healthy controls. Moreover, gaining further associations through the 
haplotype analysis of our data and a more extensive Bayesian 
statistical analysis. 
• Comparing FRMD6, BIRC5 and YAP1 protein levels in induced 
sputum samples from asthmatics and controls in order to evaluate role 
of Hippo signalling pathway in asthma through protein expression. 
• Investigating HeLa cells in vitro upon BIRC5 antagonist, YM155 
treatment in order to find functional roles for Hippo signalling pathway 
components, BIRC5, YAP1 and FRMD6. 
 
2. Investigation of the role of angiopoietin receptor Tie-2 in asthma and its 
phenotypes 
• Assessing the incidence of different comorbidities of asthma within 
our study population. 
• Evaluating tagSNPs of Tie2, encoded by the TEK gene, in asthmatic 






3. Investigation of associations between 60 previously identified genes and 
asthma 
• Sixty genes have been previously identified by gene expression 
microarray on an ovalbumin-induced mouse model of asthma by our 
research group (Tölgyesi et al. 2009). Following variation selection, 
identification of associations by estimation of allele frequencies 









3.1.1. Characteristics of Participants of Sputum Induction and Gene Expression 
Measurements 
 
The gene expression analysis was done using the induced sputum of 18 asthmatic 
patients and 10 healthy controls. All subjects completed a detailed, pre-edited 
questionnaire based on the ISAAC Phase Three Questionnaire. The recent Global 
Initiative for Asthma guidelines (www.ginasthma.org) were used to diagnose asthma by 
a respiratory medicine specialist. The evaluation of asthma severity was done at the time 
of acquisition of induced sputum samples from the patients based on patient history, 
including number of exacerbations per year, lung function test results, medical treatment 
applied and response to medication. Asthmatics were divided into four severity groups, 
but due to low number of patients GINA 1,2 (mild) and GINA 3,4 (moderate-severe) were 
aggregated. GINA groups of severity from 1-4 are summarised as follows. GINA 1 is 
‘intermittent’ asthma, with symptoms less than once a week and brief exacerbations. 
Nocturnal symptoms do not occur more than twice a month. FEV1 is more than 80%, 
where their variability is less than 20%. GINA 2 is ‘mild persistent’ with symptoms more 
than once a week but less than once a day and exacerbations may affect the patient’s 
activity and sleep. Nocturnal symptoms occur more than twice a month. FEV1 is more 
than 80% with variability of less than 20-30%. GINA 3 is ‘moderate persistent’ with daily 
symptoms and exacerbations affecting activity and sleep. Nocturnal symptoms occur 
more than once a week and there is a need for daily use of inhaled short-acting beta-
agonist. FEV1 is between 60-80% with a variability of more than 30%. GINA 4 is ‘severe 
persistent’ with daily symptoms and frequent exacerbations. There are also frequent 
nocturnal symptoms of asthma. The patients suffer from the limitation of physical 
activites. FEV1 is less than 60% with a variability of more than 30%. Out of the 18 
asthmatic patients, 14 regularly used inhaled corticosteroids (ICS): <500 μg/day 
beclomethasone dipropionate (BDP) or equivalent (n = 5), 500–1000 μg/day BDP or 
equivalent (n = 7) and >1000 μg/day BDP or equivalent (n = 2); while four were 
considered steroid naive. Healthy volunteers with no previous history of asthma or any 
airway conditions comprised the control group. Everyone participated in a lung function 
test (PDD-301/S, Piston Inc., Budapest, Hungary) and were assessed for fractional 
exhaled nitric oxide (FENO) levels (NIOX MINO, Aerocrine, Solna, Sweden). All 
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healthy subjects had a normal lung function and had no respiratory tract infection four 
weeks prior to the analysis. A skin prick test was also performed for common allergens 
to test the presence of atopy, which is a genetic predisposal for developing allergic 
rhinitis, atopic dermatitis and/or asthma. The participants’ sex, age, smoking habits and 
allergic statuses were compared between cases and controls and between severity groups, 
but no statistical significance was found (Ungvári et al. 2012a). Table 1 shows a summary 
of this study population. 
 
Table 1. Detailed characteristics of subjects participating in sputum and gene 
expression analysis. 











Age ± SD 43.7 ± 16.7 29.3 ± 4.6 0.01 
Sex (Male/Female) 10/8 5/4 1 
Asthma severity:    
Mild (GINA 1,2) 11 - - 
Moderate-to-severe (GINA 3,4) 7 - - 
Sputum eosinophil % 13.1 ± 12.4 0 ± 0 0.001 
Sputum neutrophil % 20.3 ± 17.9 18.1 ± 9.3 0.8 
Sputum macrophage % 59.8 ± 21.0 74.8 ± 8.2 0.2 
Sputum bronchial epithelial cell % 1.2 ± 1.6 7.1 ± 5.7 0.0007 
ICS dose (g) ± SD 594.4 ± 527.4 - - 
FENO level (ppb)± SD 22.6 ± 12.5 NA - 
FEV1 level (L) ± SD 2.3 ± 0.7 - - 
GINA: Global Initiative for Asthma; ICS: Inhaled corticosteroid in g; FENO: 
Fractional exhaled nitric oxide in parts per billion; FEV1: Forced expiratory volume in 
1 second in litres. 
 
3.1.2. Characteristics of Participants of Genotyping Analysis 
 
The genotyping analysis of YAP1 SNPs included 1233 unrelated individuals, out 
of which 522 were asthmatic children (mean age±SD: 10.20±5.31 years; 328 males and 
194 females) and 711 healthy controls (mean age±SD: 14.0±11.2; 429 males and 282 
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females). Further, the genotyping analysis of TEK SNPs included 1189 unrelated 
individuals, out of which 435 were asthmatic children (mean age±SD: 10.3 ± 4.4 years; 
269 males and 166 females) and 754 healthy controls (mean age±SD: 13.8±11.8 years; 
453 males and 297 females). Moreover, the genotyping analysis of 60 previously 
identified genes (list of genes found in Temesi et al. 2014) included 671 individuals, out 
of which 311 were asthmatic children (mean age±SD: 10.6 ± 4.8 years; 203 males and 18 
females) and 360 healthy controls (mean age±SD: 21.7 ± 13.9 years;181 males and 179 
females). The patients were all Hungarian (Caucasian), from which about 5% were of 
Gypsy origin based on state population data. Asthma was diagnosed based on GINA 
guidelines, as before (Ungvári et al. 2012a). Atopy was identified by a positive skin prick 
test and/or positive total or specified serum IgE levels. The total and specified serum IgE 
levels were evaluated with the 3gAllergy blood tests in the Immulite 2000 Immunoassay 
system (Tarrytown, NY, USA). The resulting serum IgE levels were either normal or high 
based on age-specific ranges (kU/litre). 
Different types of asthma were defined in patients. A number of participants were 
excluded from the analysis, where insufficient information was available on asthma 
phenotypes, hence altogether, 391 and 320 asthmatic children were involved in the 
phenotype analysis of YAP1 and TEK genes, respectively. Asthma was divided into 
allergic and non-allergic asthma subtypes. If asthma was not provoked by allergens, but 
allergy was also present, allergy types were, nonetheless, marked. In allergic patients 
depending on the types and quantities of allergens, subgroups of indoor, outdoor, or 
inhalative allergic phenotypes have been designated. Asthma was categorized as exercise-
induced asthma when the asthma exacerbation was provoked by exercise in the medical 
history of the patients. If the onset of asthma or the asthma exacerbations have been 
associated with an infection related acute respiratory illness the asthma was classified as 
viral-induced asthma. Non-atopic patients with viral-induced asthma phenotype 
composed the non-allergic asthma subgroup (Wenzel 2006) (Figure 2). Indoor allergens 
included dust mites, mould, pet dander and cockroaches, whereas outdoor allergens 
consisted of different types of pollen. Eosinophil cell counts from blood were measured 
with the Coulter AXM analyser, where the normal relative range was between 1-6%, and 
the normal range of absolute eosinophil count was between 50-200/μl. None of the 
patients had a change of therapy before the blood samples were taken. Neither had they 
exacerbations or respiratory infections for at least four weeks prior to the blood test. Table 
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2 shows the detailed characteristics of the asthmatic patients participating in the gene 
association study. 
The samples from the control children were collected at the Orthopaedic 
Department in the Budai Children’s Hospital or at the Urological Department in the Heim 
Pál Hospital, both in Budapest. None of the controls had any symptoms of asthma or 
airway conditions, nor any need for medication.  
A written informed consent was signed by all patients or by their parent/guardian. 
The study was carried out according to the Declaration of Helsinki and was approved by 
the Ethics Committee of the Hungarian Medical Research Council.  
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Table 2. Detailed characteristics of asthmatic patients participating in SNP analysis of 
YAP1 and TEK genes. 
Clinical and biological 
characteristics of asthmatic 
patients 
Analysis of YAP1 
SNPs 
Analysis of TEK 
SNPs 
Number of patients n=522 n=435 
Age ± SD 10.2 ± 5.3 10.3 ± 4.4 
Sex (Male/Female) 328/194 269/166 
Asthma phenotypes/sensitization 
status of subjects: 
n=486 n=320 
     Exercise-induced, yes/noᵃ 155/233 111/209 
     Viral-induced, yes/noᵃ 181/208 134/186 
     Allergic asthma, yes/noᵃ  56/82 47/60 
     Inhalative allergy, yes/noᵃ 298/99 244/75 
     Outdoor allergy, yes/noᵃ 240/149 202/117 
     Indoor allergy, yes/noᵃ 225/164 190/129 
     Comorbidity Rhinitis, yes/noᵃ 217/173 178/142 
     Comorbidity Conjunctivitis, 
     yes/noᵃ 
120/270 100/220 
GINA statusᵃ:   
     Number of patients in GINA 1 97 84 
     Number of patients in GINA 2 241 206 
     Number of patients in GINA 3 48 28 
     Number of patients in GINA 4 96 0 
Absolute eosinophil count ± SD 
(number/μl) 
300 ± 300 300 ± 300 
Number of patients with normal or 
high absolute eosinophil count 
(normal/high) 
107/154 72/127 
IgE ± SD (kU/l) 468 ± 1828 487 ± 2066 
Number of patients with normal or 
high IgE level (normal/high) 
88/182 66/143 
ᵃData are available on a limited data set only. Normal absolute eosinophil count is  
200 /μl and high absolute eosinophil count is  200 /μl. Normal IgE level is  200 kU/l, 
high IgE level is  200 kU/l. 
 
3.2. Sputum Induction 
 
Induced sputum was used for gene expression assays and Western blot analysis. 
Participants were first treated with 400μg of inhaled salbutamol, then, they inhaled 4.5% 
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saline solution generated by a De Vilbiss Nebulizer (Ultra-NebTm 2000 model 200 HI, 
Somerset, PA, USA) for 5 minutes. This procedure was repeated two more times, where 
after each sputum induction, the subjects’ pulmonary function was assessed. All samples 
were examined for salivary contamination and only those were used in the study, which 
were macroscopically free of such contamination. These samples were, then, diluted with 
phosphate buffered saline (PBS) that contained 0.1% dithiothreitol from Sigma (St Louis, 
MO, USA). The samples were thoroughly mixed with a vortex and placed on a bench 
rocker for 30 minutes at room temperature. Then, the samples were filtered with a 40μm 
Falcon cell strainer and centrifuged at 1500rpm for 10 minutes at room temperature. The 
cell pellet was resuspended in 1ml PBS. The Trypan Blue Exclusion test was used to 
determine cell viability in a Burker chamber. After differential cell count by a specialist, 
cells were stored on lysis buffer at -80°C until use (Ungvári et al. 2012a). 
 
3.3. DNA Isolation 
 
Genomic DNA was isolated from whole blood samples of 1233 individuals using 
the QIAamp blood DNA midi kit (Qiagen, Maryland, USA) or the iPrep PureLink gDNA 
Blood Kit on iPrep Purification Instrument (Invitrogen, Carslbad, CA, USA) starting out 
from 1 ml whole blood. The average DNA concentration of samples was between 30-
60ng/l measured by Nanodrop ND-1000 spectrophotometer (NanoDrop Technologies, 
Wilmington, DE). 
 
3.4. RNA Isolation and cDNA transcription 
 
RNA was isolated successfully from the induced sputum samples of 18 patients 
and 10 control subjects with the Qiagen Mini RNeasy Kit according to the manufacturer’s 
instruction (Qiagen, Maryland, USA). The total RNA quantity was measured by 
Nanodrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). The 
cDNA used in the gene expression analysis, was produced with a High Capacity cDNA 
Reverse Transcription Kit from Thermo Fisher Scientific (Thermo Fisher Scientific, 





3.5. Gene Expression with TaqMan 
 
Real-time quantitative PCR was performed on LATS1, LATS2, MST1, MST2, 
SAV1, YAP1, TAZ and β-actin genes using 7900HT Fast Real-Time PCR System (Thermo 
Fisher Scientific, Waltham, MA USA) according to the manufacturer’s instructions with 
1.5 μl cDNA/well and final volume of 25μl. β-Actin was used as an endogenous control 
and all results were normalized to it using the delta delta Ct method. 
 
3.6. SNP Selection and Genotyping with Competitive Allele-Specific PCR 
 
SNPs were selected from YAP1 gene using UCSC Genome browser. Preferably, 
promoter, missense or UTR SNPs were chosen where MAF in the Caucasian population 
was higher than 0.1, which was confirmed by HapMap. We also checked for linkage 
between SNPs and have chosen tagSNPs with Haploview 4.2 program (Broad Institute of 
MIT, Cambridge, MA, USA). TEK gene SNPs were chosen based on the paper of Ghosh 
et al. (Ghosh et al. 2016). 
KBioscience Competitive Allele-Specific PCR (KASP) version 4.0 genotyping 
assays were used (LGC Genomics, Berlin, Germany) to genotype fourteen SNPs on the 
YAP1 gene and three SNPs on the TEK gene (Table 3) according to the manufacturer’s 
instructions. PCR reactions were carried out using a 7900HT Fast Real-Time PCR System 




















Table 3. Description of selected SNPs on YAP1 and TEK and results of the genotyping. 
Gene SNP 
Position 
















rs1820453 chr11:102109604 promoter A/C 0.45 0.47 1.00 
rs7106388 chr11: 102110546 5'UTR C/T 0.45 0.48 0.82 
rs10895257 chr11:102115913 intron A/G 0.22 0.24 0.75 
rs1426398 chr11:102117330 intron C/T 0.45 0.46 1.00 
rs11225138 chr11:102123167 intron C/G 0.10 0.09 0.15 
rs1426394 chr11:102149503 intron A/G 0.29 0.31 0.05 
rs948737 chr11:102158098 intron C/T 0.33 0.36 0.08 
rs1942683 chr11:102173916 intron A/G 0.40 0.42 0.69 
rs11225161 chr11: 102199763 intron C/T 0.12 0.11 0.35 
rs1894116 chr11:102199908 intron C/T 0.12 0.12 1.00 
rs11225166 chr11:102219736 intron C/G 0.11 0.12 0.71 
rs8504 chr11:102232869 3'UTR A/G 0.42 0.44 0.49 
rs2846836 chr11:102234942 downstream C/T 0.44 0.46 1.00 




































rs581724 chr9:27187424 intron T/G 0.39 0.39 0.99 
rs3780315 chr9:27196292 intron G/A 0.47 0.44 0.000062 




3.7. SNP Selection and Genotyping with Sequenom iPLEX Gold MassARRAY of 
Previous Mouse Model Based Asthma Investigation, and Statistical Analyses 
 
 SNP selection was done based on a previous study of our group on OVA induced 
mice (Tölgyesi et al. 2009). Briefly, Tölgyesi et al. have used 6-8 weeks old BALB/c 
female pathogen-free mice, which have been made ovalbumin sensitive and were either 
treated with OVA or a placebo 1-3 times. On the 28-31st days, 4-24 hours after the first 
or third treatments mouse lungs were extracted and RNA was isolated from them. Gene 
expression analysis was done by Agilent Whole Mouse Genome Oligo Microarray 4 x 44 
K chip (GSE11911). Based on the microarray results our group has chosen 60 genes with 
a statistically significant change and a possible role in human asthma and allergy 
(Tölgyesi et al. 2009). From these genes 90 SNPs have been chosen by using UCSC 
Genome Browser, where the preferential SNPs were either promoter, missense or UTR 
region variations. Full list of genes and polymorphisms may be found in Temesi et al. 
2014, Supplementary Material 1. To genotype the selected SNPs the Sequenom iPLEX 
MassARRAY technology was used at the McGill University and Genome Quebec 
Innovation Centre, in Montreal, Canada (Temesi et al. 2014).  
 After calculating allele frequencies and deviation from Hardy-Weinberg 
Equilibrium (HWE) with DeFinetti software (Helmholtz Zentrum München, Institut für 
Humangenetik, https://ihg.gsf.de/cgi-bin/hw/hwa1.pl), statistical analysis of results was 
done by Armitage’s trend test by DeFinetti software (Temesi et al. 2014). 
 
3.8. Cell Culturing 
 
 HeLa cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% foetal bovine serum (FBS), 1% glutamine, 1% antibiotics, 1% 
nonessential amino acids and 1% pyruvate (all from Thermo Fisher Scientific, Waltham, 
MA, USA) on 37C and 5% CO2 concentration. Culture medium was replaced every 48h 
incubation time. Cells were harvested and lysed in RIPA lysis and extraction buffer 
(Thermo Fisher Scientific, Waltham, MA USA) for use as positive control during 
Western blot analysis. 
 HeLa cells were cultured on six-well plates to be treated with BIRC5 inhibitor, 
Sepantronium Bromide (YM155) (Selleck Chemicals, Munich, Germany). Powdered 




were seeded/well. Cells were treated with 1000nM, 100nM, 10nM, 1nM, 0nM YM155 or 
1% dimethyl sulfoxide (DMSO) (Sigma Aldrich, St. Louis, MO, USA) as DMSO control. 
After 48h incubation cells were harvested. 50% of cells/well were treated with RIPA lysis 
and extraction buffer (Thermo Fisher Scientific, Waltham, MA USA) for further use as 
protein and 50% of cells were treated with RLT RNeasy Lysis Buffer (Qiagen, Maryland, 
USA) for gene expression analysis. All lysed samples were stored at -80C until further 
extraction of protein or RNA. 
 
3.9. Western Blot Analysis 
 
Western blot analysis was carried out on human induced sputum samples. After 
sample preparation, cells were lysed in RIPA lysis and extraction buffer (Thermo Fisher 
Scientific, Waltham, MA USA)) supplied with Halt protease inhibitor (Thermo Fisher 
Scientific, Waltham, MA USA)) at 1X final concentration and centrifuged at 14,000 x g 
at 4°C for 15 min. Total protein content was determined by the Pierce BCA protein assay 
kit (Thermo Fisher Scientific, Waltham, MA USA) according to the manufacturer’s 
instructions. Samples were loaded on 4-20% Tris-glycine precast gels (Thermo Fisher 
Scientific, Waltham, MA USA)) then blotted onto Immun-Blot PVDF membrane (Bio-
Rad Laboratories, Hercules, CA, USA). After blocking the following antibodies were 
used. The primary antibodies were anti-FRMD6, anti-YAP1 and anti-GAPDH (Abcam, 
Cambridge, UK), respectively. The secondary antibodies were polyclonal donkey anti-
rabbit IgG HRP (Abcam, Cambridge, UK) and polyclonal goat anti-mouse 
immunoglobulins HRP (Dako, Glostrup, Denmark). The membrane was treated with 
Pierce ECL plus substrate (Thermo Fisher Scientific, Waltham, MA USA) according to 
the manufacturer’s instructions and bands were visualized on standard x-ray film (Kodak, 
Rochester, NY, USA). 
 
3.10. Bioinformatics 
3.10.1. Frequentist Statistical Analysis 
 
For sputum analysis, normalized gene-expression levels of LATS1, LATS2, MST1, 
MST2, SAV1, YAP1, TAZ and β-actin genes were compared by Mann–Whitney U test or 




exact test. Correlation studies were performed by Spearman non-parametric test. 
Differences were considered to be significant when p < 0.05.  
YAP1 SNP allele frequencies were estimated by allele counting and tested for 
deviation from HWE by the software program DeFinetti between cases and control 
subjects. For the significant deviation threshold, we used p < 0.05 value. 
SNP data were analysed using SPSS version 22 (SPSS Inc., Chicago, IL, USA) 
software. Logistic regression analyses adjusted for age and gender were used to evaluate 
the association between YAP1 genotypes and asthma, its intermediate phenotypes, the 
discretized (normal/high) serum IgE and discretized (normal/high) eosinophil levels (see 
at Subjects) and the different phenotypes. Additionally, multinomial logistic regression 
adjusted for age and gender was used for the analysis of YAP1 SNPs and GINA statuses. 
Confidence intervals (CIs) were calculated at the 95% level. Additive, dominant and 
recessive statistical models were used, which are summarized as follows. The additive 
model compares all three genotype groups, both homozygous ones and the heterozygous 
with eachother. In the recessive or dominant models, either the recessive homozygous or 
the wild type homozygous groups are compared to the heterozygous and the remaining 
homozygous groups taken together, respectively. Multiple comparisons were corrected 
for using the Benjamini-Hochberg correction, and a new significance level of p=0.004 
with the FDR < 6.5% was estimated. Haplotype analysis was carried out with the 
Haploview 4.2 program (Broad Institute of MIT, Cambridge, MA, USA). Odds ratios 
(ORs) for haplotypes were counted by VassarStats software 
(http://vassarstats.net/index.html).  
HWE was tested for TEK SNPs using the chi-square goodness-of-fit test 
implemented in the online DeFinetti HWE application, as before. The significance level 
was set to 0.01. SNP data were analysed using SPSS version 19 (SPSS Inc., Chicago, IL, 
USA) software. Logistic regression analyses adjusted for age and gender were used to 
evaluate the association between TEK genotypes and asthma, its intermediate phenotypes, 
the discretized (normal/high) serum IgE and eosinophil levels (see at Subjects) and the 
different asthma phenotypes. Multiple comparisons were corrected for using the 
Benjamini-Hochberg correction, and a new significance level of P=0.008 with the FDR 
< 4.5% was estimated. Figures were made by using Microsoft Excel 2013 (Microsoft 
Corporation, Redmond, WA, USA).  
 





Bayesian statistical analysis was carried out by the research group of dr. Péter 
Antal at the Budapest University of Technology and Economics in the Department of 
Measurement and Information Systems. Earlier, our research groups have together 
developed an alternative, systems biological statistical method, named Bayesian network 
based Bayesian multilevel analysis of relevance (BN-BMLA). Bayesian networks offer a 
rich language for genetic association studies, because they exhaustively and exactly 
represent the strongly relevant variables and their interactions through the Markov 
Blanket Set and Markov Blanket Graph features and they are able to evaluate multiple 
targets. Furthermore, this Bayesian global relevance analysis method provides posteriors, 
which are direct statements about hypotheses, thus it can also be used to construct 
probabilistic data analytic knowledge bases in genetic association studies to support 
complex querying, off-line meta-analysis, and fusion with background knowledge (Antal 
et al. 2009; Antal et al. 2014; Antal et al. 2008; Hullám et al. 2010).  
Previously the BN-BMLA method was described in detail (Gézsi et al. 2015; 
Lautner-Csorba et al. 2013; Lautner-Csorba et al. 2012; Ungvári et al. 2012b, Ungvári, 
2013; Lautner-Csorba, 2013; Gézsi, 2016), thus the following only briefly summarizes 
this approach. 
A Bayesian Network is a directed acyclic graph (DAG) that aids the discovery of 
various dependency relations between random variables by representing their joint 
probability distribution. A node in the network represents a variable and edges connecting 
two nodes represent direct dependency between those variables. To find the dependence 
relations of the variables, a DAG that best describes the dataset must be found. In most 
cases, there are many DAGs with non-negligible posteriors, but certain structural features 
may be extracted accurately. Such feature is based on the concept of strong relevance of 
a single variable or a set of variables. Bayesian learning allows the evaluation of the 
strength of the data indicating the presence of a certain feature by evaluating its a 
posteriori probability. 
The a posteriori probability can be calculated for strongly relevant variable sets 
with regard to a target variable. The strongly relevant variables have direct impact on the 
target. The a posteriori probability of the strong relevance is between 0 and 1, where 1 
means that the target (e.g. phenotypes of asthma) most certainly has a dependency 




relationship.  Posterior probabilities of strong relevance greater than or equal to 0.5 are 
regarded as relevant, above 0.75 as convincing. 
In this study 29 SNPs all in the YAP1, FRMD6 and BIRC5 genes (previously 
genotyped by others with the same methods and on the same populations (Ungvári et al. 
2012a; Ungvári et al. 2012b) were involved in the BN-BMLA analysis. Table 4 shows all 







Table 4. Summary of all SNPs included in the BN-BMLA statistical analysis.  
Gene SNP 
Position 






















OR 95% CI 
YAP1 rs1820453 chr11:102109604 promoter A/C 0.455 0.466 0.975 none >0.05 - - 




chr11:102115913 intron A/G 0.222 0.237 0.708 none >0.05 - - 




chr11:102123167 intron C/G 0.103 0.087 0.128 none >0.05 - - 
YAP1 rs1426394 chr11:102149503 intron A/G 0.294 0.313 0.055 none >0.05 - - 
YAP1 rs948737 chr11:102158098 intron C/T 0.326 0.356 0.081 none >0.05 - - 




chr11: 102199763 intron C/T 0.117 0.114 0.275 none >0.05 - - 




chr11:102219736 intron C/G 0.110 0.117 0.581 none >0.05 - - 
YAP1 rs8504 chr11:102232869 3'UTR A/G 0.319 0.338 0.477 none >0.05 - - 
YAP1 rs2846836 chr11:102234942 downstream C/T 0.439 0.459 0.979 none >0.05 - - 
YAP1 rs7115540 chr11:102267059 downstream A/G 0.360 0.354 0.306 none >0.05 - - 







































OR 95% CI 




chr14:51665483 intron G/A 0.145 0.120 0.800 none >0.05 - - 
FRMD6 rs2277495 chr14:51720248 
synonymou
s codon 
C/T 0.305 0.299 0.547 none >0.05 - - 
FRMD6 rs2277494 chr14:51720254 
synonymou
s codon 
T/C 0.251 0.258 0.201 none >0.05 - - 
FRMD6 rs7150275 chr14:51728572 3'UTR A/G 0.251 0.251 0.088 none >0.05 - - 
FRMD6 rs7149810 chr14:51728602 3'UTR A/G 0.254 0.251 0.095 none >0.05 - - 
BIRC5 rs3764384 chr17:78211647 5'UTR C/T 0.386 0.464 0.019 none >0.05 - - 
BIRC5 rs3764383 chr17:78212770 3'UTR A/G 0.280 0.300 0.031 none >0.05 - - 
BIRC5 rs8073903 chr17:78213673 5'UTR T/C 0.377 0.354 0.078 
asthma 0.004 1.46 1.13-1.89 
asthma in 
females 








chr17:78214076 5'UTR C/T 0.114 0.090 0.894 none >0.05 - - 























MAF: Minor allele frequency; HWE: Hardy-Weinberg Equilibrium. Previous results of our research group are also shown for BIRC5 and FRMD6 genes 





4.1. Results of the Investigation of the Role of the Hippo Signalling Pathway in 
Asthma 
4.1.1. Results of Gene Expression Analysis of the Hippo Signalling Pathway 
 
In the induced sputum samples of 18 asthmatics and 10 control subjects we 
measured mRNA expression of 7 members of the Hippo/YAP1 pathway. The expression 
of all genes could be detected in both cases and controls. The mean gene expression level 
of YAP1 was slightly lower in asthmatic than in control patients (p=0.032; Figure 7A). 
There were no other deviations in this respect. We investigated whether within the asthma 
group there were differences in gene expression between subgroups of patients defined 
by their GINA status, but no significant differences were found. 
During the correlation studies, we found a significant and positive correlation 
between YAP1 mRNA level and the sputum bronchial epithelial cells (r=0.575, p=0.003, 
Figure 7B). There was a significant and negative correlation between TAZ mRNA and 
sputum neutrophils (r = ˗0.509, p=0.009) and MST1 showed a significant and positive 
correlation with sputum eosinophils (r=0.425, p=0.034). There was no significant 
correlation between YAP1, TAZ, LATS1, LATS2, SAV1, MST2 or MST1 gene expression 
and other cellular components, asthma severity, age, gender, airway inflammation or 






Figure 7. A. YAP1 mRNA level in the induced sputum of asthmatic patients and 
controls. B.  Relationship between YAP1 mRNA and bronchial epithelial cell levels. 
mRNA levels were normalized and expressed according to the delta delta Ct method. 
Mann-Whitney U test (A) and Spearmann’s non-parametric correlation (B) were used. 
 
4.1.2. Results of Genotyping Analysis of YAP1 Gene 
 
We examined whether any of the SNPs in the YAP1 gene influence the 
susceptibility of asthma or its associated phenotypes. The statistically significant 
genotyping results are summarized in Table 5. There was no significant association with 
any of the SNPs and asthma susceptibility, allergic status, inhalative, outdoor, indoor 









serum IgE and eosinophil levels. However, SNP rs2846836 was significantly associated 
with exercise-induced asthma (OR=2.1 [1.3-3.4], p=0.004, power=0.83; Table 5; Figure 
8A). Additionally, distribution of genotypes of SNP rs11225138 showed a significant 
difference between GINA 1-2 and GINA 3-4 statuses in a dominant model (OR=2.8 [1.4-


















In case of rs2846836 genotypes 11, 12 and 22 indicate TT, CT and CC, respectively. In case of rs11225138 genotypes 11, 12 and 22 indicate 
GG, GC and CC, respectively. ADD: additive model; DOM: dominant model 



























































Figure 8. A. Pie chart of SNP rs2846836 in the non-exercise- and exercise-induced 
asthma groups, p-value=0.004, OR=2.01 (1.26-3.43). B. Pie chart of SNP rs11225138 
in the mild and moderate-to-severe asthma groups. p-value=0.003, OR=2.80 (1.40-
5.57). Percentages were calculated from case numbers. 
 
4.1.3. Bayesian Results of Genotyping Analysis of YAP1 Gene 
 
Based on the results after genotyping 29 SNPs in YAP1, FRMD6 and BIRC5 
genes, the laboratory data and the characteristics of the asthmatic participants detailed in 
Table 2, the a posteriori probabilities of relevance between the variables with respect to 
target variables were calculated by BN-BMLA.  
Table 6 shows the most relevant variables with high posteriori probabilities 
according to the BN-BMLA analysis. As expected, e.g. eosinophil levels and allergic 
conjunctivitis are highly relevant to allergic rhinitis. In the case of genetic variations, no 


























between rs9671722 in the FRMD6 gene and exercise-induced asthma with a posterior 
probability of strong relevance of 0.99. Figure 9 shows the most likely subgraph of the 
dependence structure of the variables. This structure suggests a direct relevance of 
rs9671722 to exercise-induced asthma, while another SNP (rs3751464) of the FRMD6 
gene was found to be directly relevant to allergic rhinitis and transitively associated 
through allergic rhinitis with exercise-induced asthma.  
 
Table 6. The most relevant results of the BN-BMLA statistical method. Numbers show 
the a posteriori probability of the strong relevance of a given variable with respect to 














Non-allergic asthma 0.90 
Allergic conjunctivitis 0.78 
Allergic rhinitis 0.99 
rs9671722 (FRMD6) 0.99 











IgE level 0.75 
Inhalative allergy 1.00 
   







 Inhalative allergy 0.88 
Allergic conjunctivitis 1.00 







Figure 9. Directed acyclic graph of the most likely relations of variants and targets. 
The directed edges represent only probabilistic relationships between the variables 
which are not necessary causal. SNPs rs3751464 and rs9671722 are FRMD6 
polymorphisms. 
 
The relationship was confirmed by logistic regression which showed that patients 
with GG genotypes of the rs9671722 SNP had the highest likelihood of having both 
allergic rhinitis and exercise-induced asthma (OR=18.0 (5.9-54.9); p=3.7E-7); Table 7). 
The interaction term in the logistic regression model was significant (p = 0.01).  
In Figure 10, another type of graph is presented which shows a dendrogram of the subsets 
of strongly relevant variables with respect to allergic rhinitis.  
 
Table 7. Verification of Bayesian results by logistic regression regarding exercise-





rs9671722 OR (95%CI) p-value 
Not present GG 1  
Present GG 18.0 (5.9-54.9) 3.7E-07 
Not present GA or AA 1.6 (0.8-3.1) 0.17 








Figure 10. Dendrogram of the subsets of strongly relevant variables with respect to 
allergic rhinitis. The nodes in the dendrogram represent strongly relevant subsets of all 
variables, and the arrows denote the broadening of the subsets. The numbers in the 
nodes show the a posteriori probability that all variables in a given subset are strongly 
relevant. SNPs rs3751464 and rs9671722 are FRMD6 polymorphisms. 
 
4.1.4 Haplotype Analysis of YAP1 SNPs 
 
In order to find more evidence for the associations, we also conducted haplotype 
analyses. There is a significant difference between patients of GINA 2 and GINA 3 when 
we compared the frequencies of a haplotype formed by the rare alleles of SNPs rs1426398 
and rs11225138, where the frequency of TC haplotype was more prevalent in GINA 3 
than in GINA 2 (28% vs. 8%; p=10-7). Furthermore, the CA haplotype from SNPs 
rs11225138 and rs1426394, also showed a significant difference when patients in the two 
GINA statuses were compared (26% vs. 7%, p=10-7). When more than two SNPs were 
included in the analysis, additional associations were found. Corresponding results can 






Figure 11. Diagram showing significant difference in the largest haplotype found 
among the examined SNPs. The haplotype of ACGTCAC of YAP1 SNPs rs1820453, 
rs7106388, rs10895257, rs1426398, rs11225138, rs1426394, rs948737 between mild 
(GINA 2) and moderate (GINA 3) asthma severity groups (p=0.000002; OR=4.257, 
95% CI=2.393-7.573). 
 
4.1.5. Results of Western Blot Analysis 
 
Western blots were carried out on proteins of the Hippo/YAP1 pathway that 
showed significant associations with asthma or phenotypes when their genetic variations 
were examined. Earlier our research group found a strong significant association between 
a genetic variation in the FRMD6 gene and asthma (p < 0.001; Table 4 (Ungvári et al. 
2012b), as well as between several genetic variations in the BIRC5 gene and asthma (for 
all, p < 0.005; Table 4 (Ungvári et al. 2012a). Furthermore, we found that genetic 
variations and haplotypes in the YAP1 gene are associated with different phenotypes of 
asthma.  
The signal for the FRMD6 protein could be detected in all sputum samples from 
both asthmatic and control patients.  Unfortunately, the BIRC5 protein could not be 
detected in any of the healthy or asthmatic samples. Interestingly, however, the YAP1 




seen in the sputum samples of the mild asthmatics (GINA 1,2) and was also absent from 
the sputum of severe (GINA 3,4) asthmatics (Figure 12). 
 
 
Figure 12. Western blot analysis of YAP1 and GAPDH proteins. HeLa: HeLa cell 
extract 
 
4.1.6. Results of HeLa Cell Treatment with YM155 
 
 After 48h incubation time, YM155 treatment seemed successful. As a result, in a 
Nikon light microscope we found that the higher the concentration of YM155 was, the 
less cells were found in a given well. DMSO and negative controls were similar in number 
of cells, therefore DMSO had no visible effect on the cells. After protein expression 
analysis with Western blot, none of the investigated proteins, BIRC5, FRMD6 or YAP1 









4.2. Results of Investigation of the Role of Angiopoietin Receptor Tie-2 in Asthma 
and its Phenotypes 
4.2.1. Results of Genotyping Analysis of TEK Gene 
4.2.1.1. Prevalence of Co-morbidities Among the Asthmatic Patients 
 
The clinical characteristics of the asthmatic patients are presented in Table 2.  
Altogether, 435 asthmatic children and 754 healthy controls participated in the 
genotyping study. Among the fully phenotyped 320 asthmatic patients 178 (55.6%) had 
allergic rhinitis and 100 (31.3%) had conjunctivitis. Among the rhinitis patients 98 
(55.1%) also had conjunctivitis. And two patients had conjunctivitis without rhinitis. 
 
4.2.1.2. Comparison of Gene Expressions in a Mouse Model of Asthma 
 
Our research group has previously carried out measurements of gene expression 
levels in the lungs of mice with allergic airway inflammation as well as control mice by 
Agilent Whole Mouse Genome Oligo Microarray 4x44K chips (GSE11911 record 
number in GEO database) (Tölgyesi et al. 2009). We compared the expression level of 
the genes in the lungs of mice with OVA-induced allergic airway inflammation and 
control mice. We looked at Tek, Angpt2 and Vegf genes from the Tie2 pathway, but none 
of them showed a significant difference, however the expression of Ang1 (Angpt1) was 
significantly lower in the lungs of mice with allergic airway inflammation (on average 
with 2.3-fold; corrected p = 0.001). 
 
4.2.1.3. SNP Association Study 
 
To investigate whether SNPs in the TEK gene influence the susceptibility to 
asthma or any associated phenotypes, three SNPs have been genotyped. The distribution 
of the genotypes has been checked for deviation from the Hardy-Weinberg Equilibrium 
(HWE). Unfortunately, one of the three SNPs, rs3780315, showed a significant deviation 
from the HWE in the control population (p=1.3E-5), therefore it was excluded from our 
analysis. 
We found no association between either of the two SNPs, rs581724 or rs7876024, 
and asthma (Table 8). However, SNP rs581724 was significantly associated with allergic 




the homozygote carriers of the rare allele (AA genotype) had a significantly increased 
risk of developing allergic conjunctivitis (Figure 13) within the asthmatic population.  
The risk remained significant when the whole population without conjunctivitis was 
involved in the calculation (p = 0.003; OR = 2.1 (1.3-3.6)).  
No other phenotypes (GINA status, viral- or exercise-induced asthma, allergic 
asthma, indoor, outdoor, inhalative allergies, IgE and absolute eosinophil levels, allergic 








Table 8. Results of association of TEK SNPs rs581724 and rs7870624 with asthma and allergic conjunctivitis. 
aIn case of rs581724 genotypes 11, 12 and 22 correspond to CC, AC and AA genotypes, respectively. In case of rs7876024 genotypes 11, 
12 and 22 correspond to AA, AG and GG genotypes, respectively. MAF: Minor Allele Frequency
Phenotype SNP Phenotype MAF  
Genotypea 11 Genotypea 12 Genotypea 22 Difference between 
allelic frequencies 
Recessive model 
n (%) n (%) n (%) (11+12 vs. 22) 
      P OR(95%CI) P OR(95%CI) 
Asthma 
rs581724 
Present 0.4 138 (35) 188 (48) 66 (17) 
0.3 1.1 (0.9-1.3) 0.4 1 (0.8-1.3) 
Absent 0.39 246 (38) 311 (47) 98 (15) 
rs7876024 
Present 0.24 208 (58) 126 (35) 26 (7) 
0.7 1 (0.8-1.3) 0.9 1 (0.6-1.7) 
Absent 0.25 386 (59) 216 (33) 48 (8) 




Present 0.4 31 (35) 34 (38) 24 (27) 
0.2 1.3 (0.9-1.8) 0.007 2.4 (1.3-4.4) 
Absent 0.46 68 (33) 107 (53) 28 (14) 
rs7876024 
Present 0.25 51 (62) 21 (26) 10 (12) 
1 1 (0.7-1.5) 0.045 2.6 (1-6.5) 






Figure 13. Pie chart of SNP rs581724 in the subject groups with and without allergic 
conjunctivitis, p-value=0.007, OR=2.4 (1.3-4.4). 
 
4.3. Results of SNP Association Study Based on Previous Results from Mouse Model 
of Asthma 
4.3.1. Genotyping Results of 90 SNPs 
 
 Due to missing ratios or significant deviation from HWE, 6 SNPs were excluded 
from the analysis. Besides identifying 4 SNPs on two genes to differ significantly between 
cases and controls after frequentist statistical analysis which also included correction for 
multiple testing, which are rs2240572, rs2240571 and rs3735222 on SCIN and rs32588 
on PPARGC1B (Temesi et al. 2014), we have identified two other polymorphisms that 
may be of interest in the elucidation of asthmatic mechanisms. Table 9 shows the 
characteristics of the two SNPs.  
 
Table 9.  Characteristics of SNPs rs9862203 and rs1508147 
Gene SNP Position Function Alleles 
KLF15 rs9862203 Chr3:126058362 intronic A/G 
BIRC5 rs1508147 Chr17:76222588 near-gene-3 A/G 
The table has been adapted from Temesi et al. 2014. Supplementary material 1. 
 
Table 10 shows the HWE results of SNP rs9862203 of KLF15 (Kruppel Like 
Factor 15) and rs1508147 of BIRC5. Both SNPs show a significant deviation between 




frequencies (rs9862203: p=0.04984, OR=1.293 for allele G; p=0.04359, respectively; 
rs1508147: p=0.04928, OR=1.26 for allele A; p=0.04148, respectively). These SNPs 
showed significance previous to the multiple testing correction, but have lost significance 
after it. Nonetheless, these polymorphisms may be an important finding due to their roles 












Table 10. Detail of results of statistical analysis of 90 SNPs 
The table has been adapted from Temesi et al. 2014. Supplementary material 2
Phenotype SNP Phenotype MAF  
Genotypea 11 Genotypea 12 Genotypea 22 Difference between 
allelic frequencies 
Armitage’s trend test 
n (%) n (%) n (%)  
      P OR(95%CI) P OR(95%CI) 
Asthma 
rs9862203 
Present 0.4 149 110 27 
0.04 1.3 (1.0-1.7) 0.049 1.3 
Absent 0.39 176 101 19 
rs1508147 
Present 0.24 116 135 45 
0.04 0.8 (0.6-0.9) 0.049 0.8 
Absent 0.25 114 146 72 






During our studies, we aimed to study the role of the Hippo/YAP1 signalling 
pathway in asthma or its associated phenotypes. We aimed to examine the ever-growing 
population of our asthmatic biobank in terms of genetic variations, gene expression and 
protein expression levels of the Hippo/YAP1 pathway. We also investigated 
polymorphisms of the angiopoietin receptor gene, TEK, in the pathogenesis of asthma. 
Recently, it has been shown that inflammation caused by tissue damage or 
microbial invasion has an important role in host defence mechanisms, as well as inducing 
regeneration and repairs. Furthermore, Chan et al showed that house dust mite-induced 
asthma leads to a significant increase in reactive oxygen species (ROS) production and 
DNA damage in lung tissues, especially in the bronchial epithelium (Chan et al. 2016). 
However, the mechanisms by which inflammation, ROS and DNA damage trigger 
regenerative responses, remain unclear. 
Initially, it was thought that the Hippo/YAP1 pathway played an important role in 
the regulation of organ size, on the other hand, recently it has been indicated that YAP1 
protein could also be detected in peripheral respiratory epithelial cells of the adult mouse 
lung (Lange et al. 2015). Further, it was shown, that the distribution and intensity of YAP1 
staining were increased after the depletion of club cells in the lungs. After 10 days, when 
the regeneration of the bronchiolar epithelium was complete, the YAP1 level and 
distribution was similar to that in the uninjured airway (Lange et al. 2015). Additionally, 
several indications link the Hippo pathway with oxidative stress or ROS-initiated 
signalling pathways and various pathological processes. ROS triggered signalling is also 
mediated by YAP1, the major Hippo downstream target (Mao et al. 2015). These findings 
in mice suggest that the Hippo/YAP1 pathway can also be a player in the regeneration 
processes in human asthma. 
Earlier our research group identified the FRMD6 gene through a partial genome 
screening in paediatric asthma as well as showing that it was most consistently associated 
with asthma susceptibility and its function in the asthmatic processes was also confirmed 
in an OVA-induced mouse model (Ungvári et al. 2012b). In an independent study our 
group found the genetic variations of BIRC5 to influence asthma susceptibility, 
additionally the gene expression of BIRC5 changed significantly during asthma both in 
animal and human studies (Ungvári et al. 2012a). Since it has been speculated that 




downstream target gene of YAP1, these findings also indicated that the Hippo/YAP1 
pathway might have a role in asthma. 
In the present study as well as in earlier studies we found all important members 
of the FRMD6/Hippo/YAP1 pathway to be expressed in the human induced sputum in 
both asthmatics and healthy persons. The gene expression levels of the various 
components of the Hippo pathway showed correlations with diverse cell types. This may 
be suggestive of the main sources of these mRNA in the sputum samples. It may also be 
proposed that the regulation of these mRNA expressions may be different in the implied 
cells and/or the genes have additional, diverse functions in these cells. 
  The gene expression level of YAP1 was found to be correlated with sputum 
bronchial epithelial cell number suggesting its possible origin. There was no correlation 
found between YAP1 mRNA level and the severity of asthma or other asthma phenotype. 
Interestingly, YAP1 protein could only be detected in mild asthmatics and could not be 
seen in controls or in severe asthmatics on Western blot.  
Initially, it has been suggested that YAP1 is regulated by the Hippo pathway, a 
kinase cascade that eventually phosphorylates and hence inhibits the protein. Recently, 
several studies have suggested that Hippo-mediated YAP1 phosphorylation is an essential 
input for YAP1 regulation but it is not the only one. YAP1 phosphorylation and activity 
can be regulated by inflammation, DNA damage, ROS or mechanical signals that 
represent separate signals with partly independent pathways (Figure 4) (Chan et al. 2016; 
Mao et al. 2015; Moleirinho et al. 2013; Piccolo, Dupont, and Cordenonsi 2014; Yin and 
Zhang 2015). 
The mechanisms of YAP1 inhibition by phosphorylation are nuclear exclusion, 
sequestration in the cytoplasm or proteasomal degradation. We detected YAP1 mRNA in 
all samples, but YAP1 protein could be detected only in mild asthmatics. Although the 
detection level of the RT-PCR is lower than that of the Western blot, this finding is in 
agreement with the previous notion that YAP1 activity is also and perhaps mainly 
regulated on the protein level. Of course, due to the low number of patients and the type 
of detection method used this can only be regarded as a preliminary finding. On the other 
hand, based on the above described observations, the appearance of YAP1 in the mild 
asthmatics can be explained by the asthma-associated tissue damage induced regeneration 
where the Hippo/YAP1 pathway can have an important role (Beasley et al. 1989; Jeffery 
et al. 1989; Laitinen et al. 1985). Inflammation, DNA damage and elevated ROS in the 




(Mao et al. 2015). Presently, it cannot be explained why the YAP1 protein could not be 
detected in the sputum samples of the severe asthmatics. However, it can be hypothesized 
that by an unknown mechanism YAP1 is not (or less) activated in the lung of severe 
asthmatics which can result in an impaired regeneration process in the airways which can 
contribute to the irreversible organ damage and the severity of airway remodelling in 
these patients. 
Here, we have to mention some limitations to our study.  Firstly, although Western 
blot can determine the molecular weight of the protein and in this way, has a higher 
specificity comparing to e.g. ELISA, it is less sensitive and less capable of quantitative 
measurement. Secondly, in this study we did not differentiate between dephosphorylated 
and phosphorylated YAP1. Furthermore, because we have no available data on the exact 
time points inhaled corticosteroid (ICS) were administered, we cannot exclude the 
possibility that the different time intervals between ICS administration and sputum 
induction may influence our results. 
Finding a genetic variation in the YAP1 gene to be associated with exercise-
induced asthma as well as finding a significant difference in the distributions of certain 
haplotypes and different asthma GINA statuses further supports the possible role of the 
Hippo/YAP1 pathway in asthma. The latter observation, in line with the lack of YAP1 
protein in the induced sputum of severe asthmatics, also supports the finding that 
haplotypes in the YAP1 gene associate with the severity of the disease. It must be 
mentioned, however, that there may be differences in childhood and adult asthma and 
thus the genetic associations must be confirmed in a well characterized adult population. 
Based on our genotyping results and the characteristics of the asthmatic patients, 
we searched for the most probable interaction networks with respect to different target 
variables. We also wanted to know whether there were interactions between the three 
genes (FRMD6, YAP1 and BIRC5) whose genetic variations associated with asthma or 
asthma phenotypes in this population. Using the BN-BMLA method there was no 
interaction between these genes implying that the genetic variations in the three genes 
influenced the disease susceptibility independently from each other or the studied 
population was too small to detect such interactions.  
Two genetic variations in the FRMD6 gene proved to be the most relevant to 
exercise-induced asthma and allergic rhinitis within the asthma group. The two SNPs are 
in epistatic interaction with each other through allergic rhinitis and exercise-induced 




airways after exercise. Presently, the exact mechanism of exercise-induced asthma is not 
known but as breathing through the mouth is common during exercise, there is an 
increased penetration of pollutants, cold air and allergens into the airways which can lead 
to epithelial damage, inflammation, and remodelling (Boulet and O’Byrne 2015; Weiler 
et al. 2010). Based on the literature and of our findings it is not possible to explain the 
connection between the variations in the FRMD6 gene, rhinitis and exercise-induced 
asthma, but a possible hypothesis may be that the variations in the gene can weaken the 
regeneration capacity of the Hippo pathway which can lead to persistent epithelial 
damage and asthmatic symptoms in genetically susceptible individuals.  
In our next study, we investigated whether eQTL SNPs in the TEK gene 
influenced the risk for asthma or associated phenotypes. We did not find any associations 
between these SNPs and asthma in our population, however, one of the variations showed 
a rather strong association with allergic conjunctivitis. To the best of our knowledge this 
is the first study to show that a genetic variation associates only with allergic 
conjunctivitis and not with other atopic diseases like allergic rhinitis or asthma. Figure 14 
shows the possible role of Tie2 signalling in allergic conjunctivitis. 
 
Figure 14. Possible role of Ang1-Tie2 signalling pathway in allergic conjunctivitis. 
 
However, a number of evidence indicates, that the Tie2 pathway may have a role 
in asthma. The gene expression of the main ligand of the Tie2, angiopoietin 1 was 




also supported by Simoes et al (Simoes et al. 2008). As Ang1 has an anti-inflammatory 
role in the lung by inhibiting leukocyte transendothelial migration, cytokine production 
and vascular permeability, its reduced expression may contribute to the development of 
the asthmatic airway inflammation (Simoes et al. 2008).  
Furthermore, in a recent large genome wide association study four low frequency 
SNPs on chromosome 9p21.2 were found to be significantly associated with asthma. 
Although the detected SNPs were closest to the EQTN gene, they were in LD with a 
missense variant in the TEK gene however being physically quite far from it. Because of 
this linkage and the known function of the Tie2, the TEK gene was suggested as a 
candidate gene. However, fine mapping the region showed no eQTL effects in any of the 
tissues relevant to asthma (Almoguera et al. 2016). In our study, we tested three eQTL 
SNPs within the TEK gene with known respiratory disease association, whether they 
influenced the risk for asthma or any associated phenotypes. We found no association 
with asthma, but a quite strong association with allergic conjunctivitis.  
Possibly, allergic conjunctivitis is the least well studied atopic disease. Because it 
occurs together with rhinitis in most cases, they are often studied together as 
rhinoconjunctivitis and most studies report only on either the proportion of rhinitis 
patients suffering from ocular symptoms or the associated burden (Klossek et al. 2012). 
However, not all rhinitis patients develop conjunctivitis and conjunctivitis can exist 
without rhinitis indicating a partially different genetic background. In contrast, there is 
hardly any published genetic study in allergic conjunctivitis and there are no genetic 
variants which associate only or mainly with allergic conjunctivitis. Although several 
studies illustrate that ocular symptoms could have greater negative impact on the quality 
of life of the patients than nasal problems, they are underappreciated and often under-
treated (Pitt et al. 2004; Smith et al. 2005). The presence of ocular symptoms has been 
shown to be correlated with sleep impairment, limitations in daily activities and emotional 
distress (Stull et al. 2009). 
In our study population, the prevalence of allergic conjunctivitis among the 
patients with rhinitis (55.1%) was within the range of the results of other studies (50-
65%) (Rosario and Bielory 2011). The gene for the Tie2 receptor is a plausible candidate 
gene in allergic conjunctivitis. It is highly expressed in the eye; its mutations can cause 
congenital glaucoma and it is a potential drug target in different eye diseases (Souma et 
al. 2016). The associated SNP is located in an intron near the transcription start site and 




acetylated histones and/or endothelial cell specific euchromatin. The rare allele of the 
rs581724 SNP which is associated with the increased risk to conjunctivitis is also 
associated with reduced Tie2 expression in HapMap3 population. 
Presently it cannot be explained how exactly this SNP increases the risk to 
conjunctivitis, but it has been shown that Tie2 participates in the regulation of the barrier 
function of the endothelial cells (David et al. 2013; Rübig et al. 2016). It can be 
hypothesized that the rs581724 SNP, which is associated with a lower Tie2 expression, 
can weaken this barrier function of the endothelial cells. Moreover, it is well known that 
the inflammatory response to allergens causes nearby blood vessels to dilate and become 
more permeable. It can be speculated that this second hit to the microvascular barriers 
already weakened by reduced Tie2 expression may increase the risk of the activated 
inflammatory cells leaking out of the blood vessels into the surrounding tissues in the eye 
causing the characteristic symptoms of the allergic conjunctivitis. 
Although there are different types of ophthalmic anti-allergic medications 
available for the treatment of the patients with allergic conjunctivitis, it is generally 
accepted that the patients are under-treated. E.g. in a large French study it was shown that 
despite having received treatment for ocular symptoms, in more than 20% of the patients 
the symptoms persisted indicating that the treatments were not effective (Klossek et al. 
2012). Based on our results, the Tie2 pathway can play a role in the pathomechanism of 
the disease and it is a potential novel therapeutic target in allergic conjunctivitis. In the 
last decade, several different agents that can activate the Tie2 pathway have been 
investigated in diseases where leaky blood vessels and/or downregulated Tie2 receptor 
contributed to their development. These diseases include sepsis, acute kidney injury, 
influenza, stroke and eye diseases, and it was shown that these drugs could provide 
additional benefit to the prevailing therapy (Bourdeau et al. 2016; Cui et al. 2013; David 
et al. 2013; Rübig et al. 2016; Sugiyama et al. 2015). It was also shown that compensatory 
changes in Ang1 expression might help preserve basal Tie2 signalling when Tie2 gene 
expression is low. Our results suggest that these or similar drugs might also be potential 
candidates in allergic conjunctivitis. 
In our following study, we have used a previous investigation of asthma based on 
an OVA-induced mouse model by Tölgyesi et al. This study is discussed in another 
Doctoral Thesis by Temesi, therefore I only focus and discuss my own scientific findings 
here. After gene choice, we genotyped 90 SNPs on our human biobank of asthmatics and 




an intronic SNP on the KLF15 gene and the other, rs1508147 is a near-gene SNP on the 
3’ end of the BIRC5 gene. Both of them showed a significant deviation between 
asthmatics and controls, but the significance was lost after multiple testing correction. 
Nonetheless, both SNPs and genes may have a role in the pathogenesis of asthma, hence 
I find it important to elaborate these findings. 
Identifying a difference between asthmatics and healthy controls in a regulatory 
region of BIRC5 provides further evidence for its role in asthma. Tölgyesi et al have 
previously shown that Birc5 gene expression increases in OVA-induced mice in the Th2-
type inflammation model (Tölgyesi et al. 2009). The group’s results were confirmed in a 
mouse model of asthma, where the mRNA level of Birc5 significantly correlated with the 
eosinophil level found in the mice’s bronchoalveolar lavage (Tumes, Connolly, and Dent 
2009). Furthermore, Ungvári et al has shown that BIRC5 gene expression increase in 
asthma also remains in humans, as found in the induced sputum samples of asthmatics 
and controls, as well as identifying a polymorphism that may play a role in the asthmatic 
mechanisms (Ungvári et al. 2012a). Ungvári et al has also identified the same SNP, 
rs1508147 to be slightly associated with asthma in females (OR=1.683, CI=1.096-2.585, 
p=0.017) (Ungvári et al. 2012a). This polymorphism has been found to have the highest 
impact on BIRC5 expression (Dixon et al. 2007). Ungvári et al hypothesize, that due to 
its position near the 3’end of the gene, rs1508147 may also disrupt or create miRNA 
binding sites, although they could not confirm this assumption because of the available 
miRNA predicting tool (Ungvári et al. 2012a). 
KLF15, Kruppel Like Factor 15, a transcription factor has been implicated to play 
a role in the regulation of vascular smooth and cardiac muscle functions. Recently, it has 
been shown by expression profiling that during the identification of target genes of 
glucocorticoids - that play a major role in the treatment of asthma symptoms - in human 
airway smooth muscle cells, KLF15 has a differential gene expression in the presence of 
the drug (Masuno et al. 2011) They have also confirmed the result on other airway smooth 
muscle cell lines by qPCR. Masuno et al have shown, that the difference in vitro has an 
in vivo function, as they have treated wild type and Klf15-/- mice after OVA induction 
with a synthetic glucocorticoid, and have found that the Klf15 deficient mice had a 
reduced AHR associated with the OVA challenge. They hypothesize that Klf15 in mice 
play a role in the contractility of the airways by regulating apoptosis and proliferation 
(Masuno et al. 2011). Their findings have been confirmed by Himes et al, who have used 




KLF15 was one of the differentially expressed genes they found, providing further 
evidence for its role in asthma pathogenesis (Himes et al. 2014). In addition to these 
findings, Tölgyesi et al have created an allergic airway inflammatory mouse model of 
asthma, with 3 groups of mice with a differential OVA-challenge protocol (Tölgyesi et 
al. 2009). In group 1, they have seen a quick increase in neutrophil cell count (neutrophil 
infiltration) in the inflammatory cell composition from isolated BALF, however in groups 
2 and 3, eosinophilic infiltration was seen, as the Th2-type eosinophilic airway 
inflammation and eventually airway hyperresponsiveness has developed towards the end 
of their protocol in group 3 (Tölgyesi et al. 2009). After the microarray gene expression 
experiment a significant decrease in Klf15 mRNA was seen in group 2 and a slight 
increase but nonetheless significant reduction in group 3 compared to control mice 
without OVA-challenge, but this was not seen in group 1 (Group 2 vs Control group: 
corrected p-value=0,0043, normalized log2 ratio=-1,39; Group 3 vs Control group: 
corrected p-value=0,0073, normalized log2 ratio=-1,51) (Tölgyesi et al. 2009). Therefore, 
in mice, Klf15 gene expression was reduced significantly in a systemic allergic status, but 
in comparison in the allergic airway inflammatory disease, Klf15 expression has slightly 
increased. These results further support the role of KLF15 in asthma.  
Both genes may play a role in asthma, but their functional studies are needed to 






Our study provides additional evidences that the FRMD6/Hippo/YAP1 pathways 
might have a role in asthma and its different subtypes.  
We showed that all investigated Hippo signalling pathway members were 
detectable in the induced sputum of both asthmatics and controls. 
We showed that YAP1 mRNA expression is significantly lower in asthmatics 
compared to controls and found also that the main source of YAP1 in asthmatics may be 
the bronchial epithelial cells. Additionally, more correlations have been revealed between 
Hippo member gene expressions and various cell types, suggesting their source of origin. 
We found genetic variations on the YAP1 gene to be associated with exercise-
induced asthma, and asthma severity. The latter result was also confirmed by the 
haplotype analysis. Of course, the genetic associations must be confirmed in independent 
populations. 
The BN-BMLA revealed a direct relevance of SNP rs9671722 on the FRMD6 
gene to exercise-induced asthma, while another SNP, rs3751464 from the same gene was 
found to be directly relevant to allergic rhinitis and transitively associated through allergic 
rhinitis with exercise-induced asthma, suggesting an increased importance of the 
FRMD6/Hippo/YAP1 pathway in the pathogenesis of asthma and its associated 
phenotypes. 
We found that YAP1 protein was only expressed in mild asthmatics, but neither 
in controls nor in severe asthmatics. It would be also interesting to reveal how exactly the 
activity of YAP1 protein is regulated in the airways of the asthmatic patients. If additional 
studies can confirm that the YAP1 associated pathways have a role in the regeneration 
processes in airway inflammations, these pathways can be potential novel therapeutic 
targets in asthma and other inflammatory airway diseases.  
Although several lines of evidences indicate that the Tie2 pathway might have a 
role in asthma, the investigated variations in the TEK gene, which are associated with 
lower Tie2 expression, did not influence the susceptibility to the disease.  
We found however, that the homozygote carriers of the rs581724 SNP had 
significantly increased risk to allergic conjunctivitis. If additional studies can confirm the 
role of the Tie2 pathway in allergic conjunctivitis, this can be a potential novel therapeutic 




We investigated 90 SNPs on 60 genes chosen based on a previous study on OVA-
induced mice. We have identified two SNPs, one of them, rs9862203 is an intronic SNP 
on the KLF15 gene and the other, rs1508147 is a near-gene SNP on the 3’ end of the 
BIRC5 gene. Both of them showed a significant deviation between asthmatics and 
controls, but the significance was lost after multiple testing correction. Nonetheless, both 
SNPs and genes may have a role in the pathogenesis of asthma due to their functions. 
Both genes may play a role in asthma but their functional studies are needed to better 






























Asthma is a chronic inflammatory respiratory disease influenced by a wide range 
of environmental and genetic factors. We investigated the possible roles of the 
Hippo/YAP1 associated pathway, variations in the TEK gene and 90 SNPs based on the 
results of an OVA-induced mouse model of asthma in paediatric asthma and/or associated 
phenotypes. Several lines of evidences indicate that the Hippo/YAP1 pathways might 
play a role in asthma. We compared the level of gene and protein expression of several 
members of the Hippo/YAP1 pathway. The mRNA of all the members of the 
Hippo/YAP1 pathway could be detected in the induced sputum of both controls and cases. 
The YAP1 protein could not be detected in the sputum samples of the healthy controls 
and severe asthmatics but it was detectable in mild asthmatics. Fourteen SNPs in the YAP1 
gene were genotyped on our study population. The rs2846836 of the YAP1 gene was 
significantly associated with exercise-induced asthma (OR=2.1 [1.3-3.4], p=0.004). The 
association was confirmed by haplotype analysis. With Bayesian network based Bayesian 
multilevel analysis of relevance (BN-BMLA) two genetic variations in the FRMD6 gene 
proved to be the most relevant to exercise-induced asthma and allergic rhinitis. 
The Tie2 receptor is an important player in angiogenesis. The Tie2 mRNA and 
protein are abundantly expressed in the lungs and the associated pathway also has an 
important role in the development and function of the eye. Recently, variations in the TEK 
gene, encoding Tie2, have been found associated with asthma. Three SNPs in the TEK 
gene were genotyped on our study population. The genotyped SNPs showed no 
association with asthma. However, SNP rs581724 was significantly associated with 
allergic conjunctivitis in a recessive way (p=0.007; OR=2.3 (1.3-4.4)) within the 
asthmatic population. The risk remained significant when the whole population without 
conjunctivitis was involved in the calculation (p = 0.003; OR = 2.1 (1.3-3.6)). The rare 
allele of the rs581724 SNP which is associated with the increased risk to conjunctivitis is 
also associated with reduced Tie2 expression. If additional studies can confirm the role 
of the Tie2 pathway in allergic conjunctivitis, it can be a potential novel therapeutic target 
in the disease. 
The association analysis of asthma and 90 SNPs based on a previous study of 
OVA-induced mouse model of asthma resulted in two nominally significant associations 
within the BIRC5 gene providing further evidence for the role of the 
FRMD6/Hippo/YAP1 pathway in asthma, and KLF15 gene which may play a role in the 





Az asztma krónikus gyulladásos légúti megbetegedés, amit különféle környezeti 
és genetikai tényezők is befolyásolnak. Azért, hogy jobban megértsük a betegség 
kialakulását, megvizsgáltuk a Hippo/YAP1 szignál útvonal, a TEK gén genetikai 
variációinak és egy korábbi ovalbumin indukált asztmás egér modell vizsgálat 
eredményei alapján 90 SNP lehetséges szerepét az asztmában és a hozzá kapcsolódó 
fenotípusokban. Számos bizonyíték jelzi, hogy a Hippo/YAP1 útvonal szerepet játszhat 
az asztmában. Összehasonlítottuk a Hippo útvonal több tagjának gén illetve fehérje 
expresszióját. A Hippo/YAP1 útvonal tagjainak indukált köpet mRNS szintjét 
egészségesekben is és asztmásokban is detektáltuk. A YAP1 fehérjét nem tudtuk 
kimutatni sem egészségesek sem pedig súlyos asztmások indukált köpet mintájában, 
viszont az enyhe asztmásokban találtunk a fehérjéből. Tizennégy SNP-t genotipizáltunk 
a beteg populáción. A YAP1 gén rs2846836 SNP-je szignifikánsan asszociált terheléses 
asztmával (OR=2,1 [1,3-3,4], p=0,004). Az asszociációt haplotípus elemzés is 
megerősítette. A Bayesi (BN-BMLA) elemzés során az FRMD6 gén két genetikai 
variációja bizonyult a legrelevánsabbnak terheléses asztmában és allergiás rhinitisben. 
A Tie2 receptor az angiogenezis egy fontos szereplője. A Tie2 mRNS-e és 
fehérjéje széles körben fejeződik ki a tüdőben, és a hozzá kapcsolódó útvonal fontos 
szerepet tölt be a szem fejlődésében és működésében. Nemrég a TEK (Tie2 kódoló gén) 
variációit hozták kapcsolatba az asztmával. Három TEK SNP-t genotipizáltunk beteg 
populáción. A genotipizált SNP-k nem asszociáltak az asztmával. Azonban, az rs581724 
szignifikáns asszociációt mutatott az allergiás conjunctivitis-szel (p=0,007; OR=2,3 (1,3-
4,4)) az asztmás populációban. A kockázat akkor is megmaradt, amikor az egész 
populációt belevettük a számításba (p = 0,003; OR = 2,1 (1,3-3,6)). Az rs581724 ritka 
allélja, ami kapcsolatban van a conjunctivitis megemelkedett kockázatával, szintén 
csökkent Tie2 expresszióval asszociál. Amennyiben további tanulmányok igazolják a 
Tie2 szerepét az allergiás conjunctivitis-ben, potenciális új terápiás célponttá válhat. 
Az asszociációs vizsgálat során az asztmát és 90 SNP-t vizsgáltunk egy korábbi 
OVA indukált asztmás egér tanulmány eredményei alapján. Két, nominálisan 
szignifikáns asszociációt találtunk, az egyik SNP-t a BIRC5 génen, tovább biztonyítva az 
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Haplotype GINA	2	status	in	asthma GINA	3	status	in	asthma p-value OR 95%CI
rs1820453 rs7106388 rs10895257 rs1426398 rs11225138 rs1426394 rs948737 ACGTCAC 7% 25% 0.000002 4.257 2,393-7,573
rs1820453 rs7106388 rs10895257 rs1426398 rs11225138 rs1426394 rs948737 ACATGGT 21% 14% 0.121 0.591 0,316-1,103
rs1820453 rs7106388 rs10895257 rs1426398 rs11225138 rs1426394 rs948737 CTGCGAC 56% 50% 0.313 0.792 0,511-1,228
rs1820453 rs7106388 rs10895257 rs1426398 rs11225138 rs1426394 rs948737 ACGTGGT 5% 7% 0.454 1.501 0,628-3,590
rs7106388 rs10895257 rs1426398 rs11225138 rs1426394 rs948737 CGTCAC 7% 25% 0.000002 4.257 2,393-7,573
rs7106388 rs10895257 rs1426398 rs11225138 rs1426394 rs948737 CATGGT 21% 14% 0.122 0.606 0,324-1,132
rs7106388 rs10895257 rs1426398 rs11225138 rs1426394 rs948737 TGCGAC 56% 50% 0.313 0.792 0,511-1,228
rs7106388 rs10895257 rs1426398 rs11225138 rs1426394 rs948737 CGTGGT 6% 7% 0.634 1.325 0,560-3,138
rs10895257 rs1426398 rs11225138 rs1426394 rs948737 GTCAC 8% 23% 0.000039 3.576 1,998-6,400
rs10895257 rs1426398 rs11225138 rs1426394 rs948737 ATGGT 20% 14% 0.155 0.614 0,328-1,147
rs10895257 rs1426398 rs11225138 rs1426394 rs948737 GCGAC 56% 52% 0.500 0.846 0,546-1,313
rs10895257 rs1426398 rs11225138 rs1426394 rs948737 GTGGT 6% 6% 0.810 1.124 0,451-2,800
rs10895257 rs1426398 rs11225138 rs1426394 GTCA 8% 25% 0.000005 4.009 2,265-7,095
rs10895257 rs1426398 rs11225138 rs1426394 ATGG 20% 14% 0.155 0.622 0,333-1,162
rs10895257 rs1426398 rs11225138 rs1426394 GCGA 57% 55% 0.652 0.890 0,573-1,381
rs10895257 rs1426398 rs11225138 rs1426394 GTGG 5% 5% 1.000 0.964 0,361-2,576
rs1426398 rs11225138 rs1426394 rs948737 TCAC 8% 23% 0.000039 3.576 1,998-6,400
rs1426398 rs11225138 rs1426394 rs948737 TGGT 26% 20% 0.245 0.712 0,414-1,225
rs1426398 rs11225138 rs1426394 rs948737 CGAC 56% 52% 0.500 0.846 0,546-1,313
rs1426398 rs11225138 rs1426394 TCA 8% 25% 0.000007 3.895 2,206-6,877
rs1426398 rs11225138 rs1426394 TGG 26% 18% 0.118 0.621 0,354-1,090
rs1426398 rs11225138 rs1426394 CGA 57% 55% 0.653 0.897 0,578-1,393
rs1820453 rs7106388 AC 42% 50% 0.142 1.410 0,909-2,188
rs1820453 rs7106388 CT 57% 50% 0.216 0.746 0,481-1,158
rs7106388 rs10895257 CG 21% 36% 0.001024 2.220 1,386-3,554
rs7106388 rs10895257 CA 21% 14% 0.094 0.584 0,313-1,089
rs7106388 rs10895257 TG 58% 50% 0.176 0.721 0,465-1,119
rs10895257 rs1426398 GT 21% 32% 0.017 1.799 1,112-2,910
rs10895257 rs1426398 AT 21% 14% 0.094 0.584 0,313-1,089



















Haplotype GINA	2	status	in	asthmaGINA	3	status	in	asthmap-value OR 95%CI
rs1426398 rs11225138 TC 8% 28% 0.000001 4.324 2,494-7,496
rs1426398 rs11225138 TG 34% 18% 0.002349 0.425 0,244-0,742
rs1426398 rs11225138 CG 58% 55% 0.572 0.860 0,554-1,336
rs11225138 rs1426394 CA 7% 26% 0.000001 4.497 2,540-7,960
rs11225138 rs1426394 GA 66% 55% 0.063 0.648 0,415-1,009
rs11225138 rs1426394 GG 26% 19% 0.155 0.659 0,380-1,144
rs1426394 rs948737 AC 68% 74% 0.332 1.308 0,798-2,145
rs1426394 rs948737 GT 27% 23% 0.448 0.797 0,475-1,335
rs1426394 rs948737 AT 4% 3% 0.782 0.745 0,217-2,559
rs948737 rs1942683 CG 14% 23% 0.030 1.842 1,072-3,164
rs948737 rs1942683 TA 7% 3% 0.176 0.412 0,124-1,368
rs948737 rs1942683 CA 55% 51% 0.575 0.861 0,555-1,335
rs948737 rs1942683 TG 24% 23% 0.896 0.938 0,558-1,577
rs1942683 rs11225161 AC 62% 51% 0.068 0.649 0,418-1,009
rs1942683 rs11225161 GT 9% 12% 0.349 1.387 0,704-2,734
rs1942683 rs11225161 GC 29% 33% 0.391 1.246 0,781-1,990
rs11225161 rs1894116 CT 90% 78% 0.001122 0.377 0,213-0,667
rs11225161 rs1894116 TC 10% 22% 0.001122 2.654 1,499-4,699
rs1894116 rs11225166 CC 10% 22% 0.001122 2.654 1,499-4,699
rs1894116 rs11225166 TG 90% 78% 0.002252 0.404 0,229-0,713
rs11225166 rs8504 CG 9% 23% 0.000130 3.198 1,802-5,675
rs11225166 rs8504 GG 58% 48% 0.071 0.658 0,424-1,021
rs11225166 rs8504 GA 32% 30% 0.632 0.877 0,543-1,417
rs8504 rs2846836 GT 10% 28% 0.000009 3.538 2,071-6,045
rs8504 rs2846836 GC 58% 40% 0.001576 0.481 0,307-0,752
rs8504 rs2846836 AT 32% 32% 1.000 0.997 0,624-1,592
rs2846836 rs7115540 CA 52% 34% 0.001695 0.482 0,305-0,762
rs2846836 rs7115540 TA 14% 23% 0.029 1.874 1,090-3,223
rs2846836 rs7115540 TG 29% 39% 0.068 1.563 0,991-2,466









Table S2. Summary of 90 SNPs included in the genetic association study. Adapted from Temesi et al. 2014. 
Gene SNP Position Functional 
Category 
Alleles Contorl MAF Case MAF 
ACSBG1 rs3813577 15:78527253 near-gene-5(GVS) C/T 37,94% 33,39% 
AGR2 rs706072 7:16844663 utr-variant-5-
prime(dbSNP) 
T/C 18,75% 19,84% 
AGR2 rs1459564 7:16846146 near-gene-5(GVS) A/G 33,28% 30,16% 
AGR2 rs706075 7:16846354 near-gene-5(GVS) G/T 25,22% 24,09% 
AGR2 rs10261011 7:16856487 intergenic(GVS) G/A 51,02% 49,02% 
AIF1 rs2857600 6:31582287 near-gene-5(GVS) T/C 10,66% 3,26% 
ATP6V0A4 rs10258719 7:138455988 missense(dbSNP) A/G 28,34% 29,84% 
BIRC5 rs1508147 17:76222588 near-gene-3(GVS) A/G 43,67% 38,01% 
C1QC rs6690827 1:22967496 near-gene-3(GVS) A/G 29,76% 35,32% 
C1QC rs294179 1:22974928 downstream-variant-
500B(dbSNP) 
T/C 42,65% 48,67% 
CCL2 rs2530797 17:32586094 near-gene-3(GVS) C/T 33,53% 37,03% 
CCL8 rs1821142 17:32649988 near-gene-3(GVS) T/C 3,60% 4,58% 
CCNE1 rs7257330 19:30301823 near-gene-5(GVS) A/G 39,49% 38,62% 
CD6 rs1050922 11:60785352 synonymous-
codon(dbSNP) 
G/A 31,54% 33,39% 
CD84 rs1055880 1:160517692 utr-variant-3-
prime(dbSNP) 
T/C 34,24% 33,50% 
CHIA rs17027410 1:111861822 synonymous-
codon(dbSNP) 
A/G 11,64% 11,26% 
CLEC4E rs7299659 12:8696661 intergenic(GVS) A/G 19,05% 18,61% 








Gene SNP Position Functional 
Category 
Alleles Contorl MAF Case MAF 
CREB3L4 rs11264743 1:153941514 missense(dbSNP) T/C 31,12% 30,03% 
CXCL1 rs3117604 4:74734668 near-gene-5(GVS) T/C 29,30% 31,25% 
CXCL5 rs352045 4:74864687 near-gene-5(GVS) T/G 11,77% 13,11% 
CSF2 rs27438 5:131413255 near-gene-3(GVS) A/G 22,73% 22,50% 
E2F7 rs310830 12:77419593 synonymous-
codon(dbSNP) 
G/A 10,06% 13,87% 
FABP3 rs16834408 1:31837942 near-gene-3(GVS) A/G 15,92% 22,02% 
FABP3 rs10914367 1:31846206 near-gene-5(GVS) A/G 24,09% 22,20% 
FXYD4 rs4245604 10:43866528 near-gene-5(GVS) A/C 32,41% 31,64% 
GPR160 rs4955711 3:169753570 intergenic(GVS) G/A 27,96% 28,14% 
ICOS rs3923093 2:204798020 intergenic(GVS) T/C 24,15% 25,17% 
IL17RB rs2289205 3:53878616 intron-
variant(dbSNP) 
T/C 29,94% 31,38% 
IL1A rs1878320 2:113544467 upstream-variant-
2kb(dbSNP) 
C/T 30,15% 28,31% 
IL1A rs3783520 2:113544339 upstream-variant-
2kb(dbSNP) 
T/C 29,41% 27,93% 
IL1B rs16944 2:113594867 upstream-variant-
2kb(dbSNP) 
G/A 39,02% 33,50% 
IL1RL1 rs12905 2:102960007 utr-variant-3-
prime(dbSNP) 
A/G 25,00% 26,99% 
IL6 rs2069827 7:22765456 utr-variant-3-
prime(dbSNP) 
T/G 11,05% 10,98% 
IL6 rs2069832 7:22767433 intron-
variant(dbSNP) 








Gene SNP Position Functional 
Category 
Alleles Contorl MAF Case MAF 
ITGAX rs11150614 16:31366016 upstream-variant-
2kb(dbSNP) 
A/G 29,31% 28,95% 
ITLN1 rs4656958 1:160856964 intergenic(GVS) A/G 32,56% 25,90% 
ITLN1 rs2274910 1:160852046 intron-
variant(dbSNP) 
T/C 33,43% 27,30% 
KLF15 rs1358087 3:126078890 intergenic(GVS) C/T 36,36% 35,88% 
KLF15 rs9862203 3:126058362 intergenic(GVS) A/G 23,48% 28,67% 
LAPTM5 rs3762296 1:31231386 near-gene-5(GVS) G/A 48,02% 45,07% 
LGALS3 rs7160110 14:55594635 upstream-variant-
2kb(dbSNP) 
G/A 40,54% 37,16% 
LGMN rs9791 14:93170993 synonymous-
codon(dbSNP) 
T/C 42,21% 35,22% 
LY86 rs760894 6:6656198 near-gene-3(GVS) G/A 32,48% 30,62% 
LY9 rs509749 1:160793560 missense(dbSNP) A/G 50,94% 47,05% 
LY9 rs474131 1:160793442 synonymous-
codon(dbSNP) 
A/G 46,44% 39,29% 
MAFB rs6102095 20:39320751 intergenic(GVS) A/G 17,25% 15,24% 
MAP3K6 rs11247639 1:27679692 intron-
variant(dbSNP) 
G/A 32,65% 30,54% 
MARCO rs6748401 2:119698057 near-gene-5(GVS) G/A 50,45% 44,43% 
MAT1A rs3827869 10:82031278 downstream-variant-
500B(dbSNP) 
T/C 21,00% 16,44% 
MAT1A rs10887711 10:82034842 synonymous-
codon(dbSNP) 
A/G 31,53% 39,53% 








Gene SNP Position Functional 
Category 
Alleles Contorl MAF Case MAF 
MAT1A rs10749550 10:82031197 downstream-variant-
500B(dbSNP) 
A/G 35,99% 37,54% 
MKI67 rs11016071 10:129901393 missense(dbSNP) C/T 14,88% 16,83% 
MKI67 rs10082432 10:129901722 synonymous-
codon(dbSNP) 
A/G 17,70% 18,12% 
MKI67 rs8473 10:129899578 missense(dbSNP) C/T 45,22% 45,73% 
MKI67 rs2152143 10:129906980 missense(dbSNP) A/G 30,78% 28,85% 
MS4A7 rs10750936 11:60144180 near-gene-5(GVS) G/A 36,76% 34,75% 
OSGIN1 rs2432561 16:83982670 intergenic(GVS) A/G 16,74% 10,82% 
PPARGC1B rs32588 5:149200043 synonymous-
codon(dbSNP) 
C/T 23,46% 14,73% 
PTPN7 rs4359077 1:202129112 utr-variant-5-
prime(dbSNP) 
A/G 10,59% 10,70% 
RETNLB rs3811687 3:108476519 near-gene-5(GVS) T/C 29,97% 29,61% 
RETNLB rs10933959 3:108476205 near-gene-5(GVS) G/A 23,11% 19,18% 
RETNLB rs9870145 3:108477874 near-gene-5(GVS) T/A 14,93% 16,45% 
RETNLB rs11708527 3:108475974 missense(dbSNP) A/G 29,94% 29,67% 
SAA1 rs4638289 11:18285774 intergenic(GVS) A/T 38,37% 41,48% 
SAA1 rs11603089 11:18282051 intergenic(GVS) G/A 16,13% 15,08% 
SAA2 rs7130337 11:18270605 near-gene-5(GVS) A/G 24,42% 26,66% 
SCIN rs3173628 7:12627245 intron-
variant(dbSNP) 
A/G 41,28% 49,83% 
SCIN rs2240572 7:12610594 missense(dbSNP) G/A 48,69% 37,66% 
SCIN rs2240571 7:12609988 near-gene-5(GVS) C/G 39,80% 50,00% 








Gene SNP Position Functional 
Category 
Alleles Contorl MAF Case MAF 
SIGLEC1 rs625372 20:3684729 missense(dbSNP) T/C 32,04% 31,94% 
SLAMF9 rs16831153 1:159920719 near-gene-3(GVS) A/G 17,85% 18,90% 
SLC26A4 rs2248465 7:107303628 intron-
variant(dbSNP) 
C/T 26,33% 29,17% 
SLC26A4 rs2701684 7:107299527 near-gene-5(GVS) A/G 32,36% 34,65% 
SLC26A4 rs2701685 7:107299584 near-gene-5(GVS) A/G 23,51% 25,99% 
SLC26A4 rs2712228 7:107300340 near-gene-5(GVS) C/A 30,15% 30,53% 
TBXAS1 rs12532701 7:139521534 intron-
variant(dbSNP) 
G/A 43,07% 46,73% 
TFF1 rs184432 21:43787562 near-gene-5(GVS) A/G 31,83% 28,29% 
TFF1 rs225359 21:43787436 near-gene-5(GVS) A/G 33,28% 30,96% 
TFF2 rs225340 21:43772947 near-gene-5(GVS) T/C 44,77% 41,86% 
TFF2 rs3814896 21:43771711 near-gene-5(GVS) G/A 33,92% 30,84% 
TFF2 rs225333 21:43764496 near-gene-3(GVS) A/G 28,14% 27,21% 
TIMP3 rs137487 22:33259104 intron-
variant(dbSNP) 
A/G 47,28% 45,86% 
TK1 rs1065769 17:76170735 utr-variant-3-
prime(dbSNP) 
T/C 32,44% 31,17% 
TSLP rs3806932 5:110405675 near-gene-5(GVS) G/A 38,89% 40,58% 
UBE2T rs14451 1:202304868 synonymous-
codon(dbSNP) 
C/T 44,31% 47,56% 
ULBP1 rs1853665 6:150298842 intergenic(GVS) T/C 19,58% 17,07% 
ULBP1 rs4425606 6:150284435 near-gene-5(GVS) G/A 18,39% 17,83% 
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